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ABSTRACT 
Alzheimer's disease (AD) is characterized histopathologically by neurofibrillary 
tangles, senile plaques, reactive astrocytes and microglia, neuronal shrinkage, and cell loss 
in various brain regions. These pathological changes are associated with neurochemical 
deficits and cognitive impairments. Senile plaques consist predominantly of amyloid-P (APl 
peptide, that has been proposed to have a prominent role in the pathogenesis of AD. The 
main component of the tangles is paired helical filaments, which consist largely of the 
protein tau in an abnormal state of phosphorylation. There is currently no treatment 
available that effectively slows or halts the progression of AD. The main reason for this is 
the relative lack of an animal model that has the features of the disease, in which potential 
therapeutic drugs could be screened. The main objective of this dissertation work was to 
develop a rat model of the histopathological hallmarks of AD. 
Because the early and primary histopathological changes in AD are predominantly 
found in temporal lobe structures, it was determined if intra-amygdaloid injections of AP 25-
35 in the rat induced the appearance of abnormal tau proteins and reactive astrocytes as 
seen in AD. It was also examined if the effects of AP were time dependent, included 
neuronal shrinkage and microglial activation, and if these changes were associated with 
neurochemical and behavioral alterations. 
AP induced abnormal neuronal tau staining in the right amygdala and hippocampus. 
AP also induced reactive astrocytosis and neuronal shrinkage within the right hippocampus 
and amygdala, respectively. The same brain regions within the left hemisphere were 
significantly less affected. In addition, AP appeared to induce microglial proliferation and 
xi 
neuronal interleukin-1 P staining. The histopathological effects of AP peaked at 32 days 
postoperatively and were associated with minimal behavioral impairments. These effects 
were not associated with a reduction in amygdaloid choline acetyltransferase activity at 32 
days postinjection. 
These data demonstrate that intra-amygdaloid injections of AP induce transsynaptic 
cytoskeletal and astrogliotic reactions. These findings also suggest a laterality in the 
histopathological effects of AP and that the effects of single injections are in part transient. 
Identification of the cause for the lateralized effect of AP may prove valuable for 
understanding the etiology of AD and provide possible therapeutic strategies designed to 
slow the progression of the disease. In addition, these results suggest a direct association 
between plaque and tangle formation in AD, and support the use of this rat model to screen 
drugs that may alter the initial pathological events associated with AD. 
xii 
CHAPTER I 
INTRODUCTION 
Alzheimer's disease (AD) was originally characterized by Alo is Alzheimer in 1 907. 
The histopathological characteristics of AD include neurofibrillary tangles, senile plaques, 
reactive astrocytes and microglia, neuronal shrinkage, and cell loss in several brain regions. 
These pathological changes are associated with neurochemical deficits and cognitive 
impairments. The main component of the neurofibrillary tangles is paired helical filaments 
( 168,335), that consist largely of the microtubule associated protein tau in an abnormal 
state of phosphorylation (171, 183,355,356). Reactive astrocytes and microglia have larger 
cytoplasm and thicker and more branched processes than they do when in their resting 
states. Senile plaques in the AD brain are associated with reactive astrocytes 
(70, 126, 128,250) and microglia (122, 155,228). Senile plaques consist predominantly of 
amyloid-J3 ( AJ3) 1-42 peptide (103,214,233,285), which is derived from a large membrane 
spanning protein, the amyloid-J3 precursor protein (APP) ( 1 66). Mutations in APP in some 
forms of familial AD are associated with an elevated production of AJ3 (33,39,331 ). APP is 
overexpressed in Down's syndrome (248,291), and individuals with this disease invariably 
develop the neuropathological hallmarks of AD (23, 187). The proposed role for AJ3 in the 
pathogenesis of AD is further supported by the neurotoxicity of AJ3 (369,370), which 
includes amino acids 25-35 of the peptide (370). Currently, AD is the fourth leading cause 
of death in the developed world. Advanced age is the major risk factor for AD, and the 
prevalence of AD is expected to rise substantially in the near future because of the aging 
population. Numerous advances have been made in recent years in elucidating the 
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mechanism of neuronal degeneration in AD. Several risk factors for AD are now known but 
the sequence of pathogenic events that eventually lead to dementia remains a mystery. 
There is currently no treatment available that effectively slows or halts the progression of 
the disease. The main reason for this is a lack of an adequate animal model that has all the 
features of the disease, in which potential therapeutic drugs could be screened. The main 
objective of this dissertation work was to develop a rat model of the histopathological 
hallmarks of AD. 
Because the early and primary histopathological changes in AD are predominantly 
found in temporal lobe structures, we assessed the hypotheses that A~ 25-35 injections into 
the amygdala of the rat would induce the appearance of abnormal microtubule associated 
protein tau and reactive astrocytes as seen in AD. We also tested the hypotheses that the 
effects of A~ 25-35 would be time dependent and include neuronal shrinkage and microglial 
activation. Furthermore, we examined the hypotheses that these histological changes would 
be associated with neurochemical and behavioral alterations. 
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REVIEW OF THE RELEVANT LITERATURE 
Amyloid-13 Precursor Protein 
Three major isoforms of APP are produced by alternative splicing. lsoforms of 751 
and 770 amino acids are expressed in both neural and non-neural tissue (169,275,333), 
whereas a 695 amino acid isoform is mostly expressed in neurons (172,365). APP is 
processed through at least two proteolytic pathways. The major pathway is a secretory 
pathway which leads to cleavage of APP within the extracellular portion of the AP peptide 
(between residues 16 and 17) (78), that generates a 90-100 kDa secreted form (APPs) 
(78,318,349). This cleavage is performed by an unknown enzyme named a-secretase. This 
pathway is considered non-amyloidogenic because intact AP is not formed. APP also is 
processed through an amyloidogenic endosomal/lysosomal pathway (44,80, 107, 119). This 
alternative pathway generates intact AP that is processed from APP by unknown enzymes 
termed P- and y-secretase. It was believed that intact AP was not generated during normal 
APP processing (31 8), but it has recently been demonstrated that AP is produced and 
secreted during normal metabolism (24, 120,307,313). Analysis of APP metabolism in 
primary cell cultures of neurons, astrocytes and microglia indicates that neurons generate 
more AP than astrocytes or microglia ( 1 90). 
APP f3 a y 
'' ' I I 
Af3 1 - 42 
Figure 1. APP processing enzymes. Schematic presentation of the enzymatic cleavage of 
APP. A cleavage of APP by ~- and y-secretases is considered amyloidogenic because it 
leads to the production of A~ 1-42, the most prominent form of A~ in senile plaques. 
Alternatively, a cleavage by a-secretase is considered non-amyloidogenic because intact A~ 
is not formed. The arrows labeled a, ~. and y represent the respective secretases. 
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The role of APP, APPs and A~ in the brain is not well understood. APP associates 
with G proteins (251 ), suggesting that it may serve as a receptor. Overexpression of APP 
has synaptotrophic effects in the cortex of transgenic mice and protects against the 
neurotoxicity of the gp 120 protein found in the human immunodeficiency virus (240,241 ). 
APP is not essential during development because homozygous APP-knockout mice proceed 
through gestation normally (371 ). As adults, they are fertile but exhibit a 15-20% decrease 
in body weight, decreased locomotor activity, and a loss of forelimb grip strength. Diffuse 
reactive gliosis is observed in the brains of these animals without clear neuronal 
degeneration. 
Cerebrospinal fluid levels of APPs are decreased in AD (339). APPs stimulates cell 
growth (295), promotes cell adhesion (20,38, 167,234,303), and mediates the effects of 
nerve growth factor on neurite outgrowth (234). At the molecular level, APPs activates 
potassium channels (96) and increases the activity of microtubule associated protein kinase 
( 11 6). APPs protects cultured neurons from the damaging effects of glucose deprivation, 
excitatory amino acids, and oxidation, possibly through stabilization of intracellular calcium 
(217 ,302). It is possible that a reduction in the production of APPs is associated with an 
increase in A~ production, both of which would result in increased neuronal vulnerability to 
toxic insults. 
AB Peptide 
The proposed direct role for Al3 in the pathogenesis of AD is supported by the 
association of AD with inherited APP mutations; APP overexpression in Down's syndrome; 
and, the neurotoxicity of Al3 fibrils. 
H2 N-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-
Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-lle-lle-Gly-Leu-Met-Val-Gly-Gly-Val-Val-lle-Ala-OH 
Figure 2. Amino acid sequence of Al3 1-42 and Aj3 25-35 (underlined). 
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Normal processing of APP results in more production of Al3 1-40 than Aj3 1-42 
(331,336). The preferential deposition of Al3 1-42 in senile plaques (285) is likely due to its 
lesser solubility than Al3 1-40, and that it is more prone to aggregate and form 13-pleated 
sheets (11,22,81, 124, 161, 162). The first APP mutation found in AD kindreds was 
identified at codon 71 7 ( 1 04). Expression of this mutant APP in cultured cells results in 
increased production of Al3 1-42 (331). Another inherited double APP mutation at codons 
670 and 671 (242) results in an increase in Al3 production in transfected cells (33,39). APP 
is overexpressed in Down's syndrome (248,291) and individuals with this disease invariably 
develop the neuropathological hallmarks of AD (23, 1 87). 
In vitro studies indicate that Al3 1-28 has a neurotrophic effect on cultured 
hippocampal neurons (353), and that Al3 25-35 is a neurotrophic factor at low 
concentrations (nM) in differentiating neurons but is neurotoxic at high concentrations (µM) 
in mature neurons (370). Al3 toxicity in cell culture (273,284,368-370) depends on its 
aggregation state (25,220,269,273), and requires the assembly of Aj3 into amyloid fibrils 
composed of a 13-pleated sheet structure (26, 144,203). These in vitro findings correlate 
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well with the observation that histopathological changes in AD are associated with senile 
plaques that are composed of A~ fibrils, but not with diffuse plaques composed of 
amorphous A~ aggregates (210,366). Various compounds bind to A~ and enhance its 
fibrillation in vitro, including apolipoprotein E (ApoE) (205,296,326,359), heparan sulfate 
proteoglycan (90), and aluminum, iron and zinc ions (29,83,213). In addition, metal-
catalyzed oxidation of AP results in the formation of highly insoluble aggregates (71). A~ in 
vitro develops resistance to protease degradation when polymerized into fibrils (252). Other 
amyloidogenic peptides also are toxic to neurons in vitro, including amylin, serum amyloid P 
component, and a peptide derived from the prion protein (87,202,222,338). These findings 
suggest that the tertiary structure of the fibril, rather than its amino acid sequence, is 
responsible for its toxicity. 
A~ 1-42 has been shown to bind to the serpin-enzyme complex (SEC) receptor on 
cultured hepatoma cells (165). AP 25-35, 31-35, 1-39, and A~ 1-40 have similar affinity as 
A~ 1-42 for the receptor ( 1 9). The SEC receptor is present on PC 12 cells as well as in 
primary culture of murine cortical neurons, and the selectivity of neuronal SEC receptor for 
A~ is identical to that of hepatoma cells (19). The SEC receptor has been demonstrated to 
mediate internalization and degradation of AP in PC12 cells (19). In addition, this receptor 
recognizes the soluble non-toxic AP but not the aggregated cytotoxic AP, suggesting that 
the receptor may have a protective role by mediating clearance and metabolism of soluble 
A~ ( 1 8). Furthermore, AP binds to the receptor for advanced glycation end products 
(RAGE) in neurons, microglia and vascular endothelial cells (367). This interaction mediates 
cell adhesion to AP and induces production of reactive oxygen species in microglia. The 
class A scavenger receptor has also been demonstrated to mediate adhesion of microglia to 
A~ that causes secretion of reactive oxygen species and cell immobilization (76). In 
addition, A~ has been observed to form an ion channel in artificial lipid membranes (6). 
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A~ in vitro has been observed to potentiate the neurotoxicity of excitatory amino 
acids (170,218), glucose deprivation (48), and oxidative stress (196). Conversely, other 
studies have reported that glutamate antagonists do not prevent A~ toxicity (28,269). A~ 
also impairs mitochondrial redox activity and increases the generation of free radicals 
(14,308). Some reports have suggested that antioxidants inhibit the toxicity of A~ and 
other amyloidogenic peptides (14), whereas other studies find no protective effect of the 
same antioxidants (196,202). The neurotoxicity of A~ and other amyloidogenic peptides has 
been shown to be mediated by an increase in intracellular calcium (218,219), but calcium 
channel blockers and calcium chelating agents do not inhibit A~ neurotoxicity (202,352). 
These discrepancies, which may be due to differences in culture conditions, clearly 
demonstrate the limitations of in vitro culture systems and show that caution must be taken 
in extrapolating in vitro findings to in vivo situations. 
The two basic pathways or mechanisms of cell death are necrosis and apoptosis. In 
vitro studies have observed that A~ induces both apoptosis (88,200,347) and necrosis (13). 
Another amyloidogenic peptide, amylin, has been shown to induce apoptosis in pancreatic 
islet cells (202). Some neurons in AD brain appear to undergo apoptosis (2, 189,328), and 
cortical neurons from Down's syndrome brains generate increased levels of reactive oxygen 
species that leads to apoptotic cell death in culture (27). 
The reproducibility of A~ toxicity in vivo has been inconsistent 
(42,91,99, 101, 102, 178, 180,314,320,354). This may be due to variations in: 1) the 
conformational state (25,269,273), dose, and sequence of A~; 2) method of administration; 
3) pathological endpoints measured; 4) what brain region and/or hemisphere is injected; 5) 
postoperative interval; and, 6) species and/or strain used. The consistency and persistence 
of A~ deposits within the brain may also depend on similar factors. A~ in vitro develops 
protease resistance to degradation when polymerized into fibrils (252). The presence of 
heparan sulfate proteoglycans has been shown to be important for consistent in vivo 
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deposition of AP 1-40 and persistence of fibrillar AP in the rat hippocampus (321 ). Also, AP 
25-35 deposits within the rat nucleus basalis are degraded more rapidly than AP 1-40 
deposits ( 102). Furthermore, acetylcholinesterase (AChE) has been shown to promote the 
formation of and/or stabilization of AP fibrils ( 1 50). 
It can be argued that because AP 1-42 is the most prevalent form of AP in senile 
plaques, it is appropriate to use that peptide for injections into brain instead of AP 25-35. 
However, the main problem with using AP 1-42 is its insolubility in physiological solvents. 
Therefore, there is a risk of potentially toxic solvents interfering with the properties and 
effects of AP 1-42. On the other hand, AP 25-35 is readily soluble in H20 and acquires the 
same p-pleated sheet conformation as AP 1-42, which is the toxic conformation of AP. 
Only recently have a few studies demonstrated a direct association between plaque 
and tangle formation in AD. In vitro studies have demonstrated that AP increases tau 
protein kinase I (TPK I) activity (332), induces abnormal tau immunoreactivity (IR) (26,207), 
and that the neuronal death caused by AP can be prevented with TPK I antisense 
oligonucleotides (332). These findings suggest an association between plaque and tangle 
formation in AD. A few in vivo studies have investigated the effects of AP injected into the 
central nervous system (CNS) on tau IR (42,91,99, 178, 180,274). Some of these studies 
indicate that AP can induce the appearance of abnormal tau proteins in the vicinity of the 
injection site (rat cerebral cortex and hippocampus) (91, 178, 180). Other studies have failed 
to show any effect (42,99,274). For the most part, these in vivo studies have only been 
qualitative or descriptive in nature. No attempts have been made to quantify AP induced 
effects by counting neuronal tau IR cells. 
The effects of AP on tau IR may be mediated through an increase in intracellular 
calcium. AP has been shown to increase intracellular calcium (7,218), and calcium influx in 
cultured rat hippocampal neurons caused by glutamate induces tau IR as recognized by the 
antibodies Alz-50 and 5E2 (21 6). Protein kinases are generally activated by increases in 
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intracellular calcium and several of those have been shown to phosphorylate different sites 
on tau proteins (238). Therefore, AP may increase the phosphorylation of tau proteins 
through an activation of kinases mediated by an increase in intracellular calcium. The 
activities of some phosphatases that may dephosphorylate tau proteins have been shown to 
be decreased in AD (111,311 ). Therefore, AP 25-35 may also be decreasing the 
dephosphorylation of tau proteins through an inhibition of phosphatases. 
Effects of Al3 Peptide on Behavior 
Only a few studies have investigated the effects of AP injections on behavior and 
the experimental procedures vary substantially. It is, therefore, appropriate to give a 
somewhat detailed description of these findings. Because of the nature of behavioral 
experiments, it is necessary to support alterations in behavior with neurochemical and/or 
histological findings. 
Flood et al. (85) observed that intracerebroventricular (i.c.v.) administration in mice 
of [Gin 11 lAP 1-28, AP 12-28, AP 18-28 and AP 12-20 immediately after training in a 
footshock active avoidance test caused dose dependent retention deficits in the same test 
one week later. This effect may be specific to memory processing because the peptides did 
not cause amnesia when injected 24 h after training nor did they disturb storage or retrieval 
of older memories. lntrahippocampal injection of [Gln11 lAP 1-28 produced amnesia at 
much lower doses ( < 1 nmol) than an i.c.v. injection (approximately 1.5 - 6 nmol). 
Maurice et al. (221) showed that AP 25-35 injected i.c.v. in mice induced dose 
dependent decreases in both alternation behavior in the Y-maze 6 days postinjection and 
passive avoidance test 7-8 days postoperatively, at doses of 3 and 9 nmol/mouse. Both the 
cholinesterase inhibitor tacrine and the nicotinic receptor agonist (-)-nicotine induced a dose 
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dependent abrogation of the A~ 25-35 induced behavioral impairments. Furthermore, 
tacrine also reversed A~ 25-35 induced impairment of place learning and retention in a 
water maze. A moderate bilateral cell loss and Congo red positive amyloid deposits were 
observed at 21 days postoperatively within the frontoparietal cortex and in the CA3 region 
of the hippocampal formation in animals that received 9 nmol A~ 25-35. These results 
indic~te that the deposition of A~ in the brain is in some way related to impairment of 
learning and cholinergic degeneration, and furthermore suggest that the 25-35 fragment of 
A~ that is sufficient to induce neuronal death in cultures also induces an AD type amnesia in 
mice. 
One of the first studies to demonstrate a behavioral effect of A~ in rats was 
performed by Tate et al. (334), and did not use injections of A~ but rather a grafting of 
transfected cells that overexpress A~. These cells were grafted into the suprachiasmatic 
nuclei of adult rats and led to disruption of circadian activity. AD patients exhibit 
irregularities in the patterns of circadian rhythms and this finding suggests that A~ may have 
a role in these changes. However, it should be noted that the control groups did not include 
animals grafted with non-transfected cells. 
Nabeshima et al. (244) demonstrated that continuous infusions of A~ 1-40 (3, 30 
and 300 pmol/day) for two weeks into the cerebral ventricles in adult rats led to impaired 
performance in water maze (9-1 3 days postinfusion) and passive avoidance tasks ( 14-1 5 
days postinfusion). These behavioral impairments were associated with a moderate 
reduction in choline acetyltransferase (ChAT) activity in the frontal cortex (3 and 30 
pmol/day) and hippocampus (300 pmol/day). No differences were observed in AChE activity 
between treatment groups. Also, ltoh et al. ( 1 56) demonstrated in this model that A~ 
infusions (300 pmol/day) reduced nicotine stimulated release of acetylcholine and dopamine 
determined 11-13 days postoperatively by an in vivo brain microdialysis method. 
Furthermore, dopamine release induced by high potassium stimulation was also decreased in 
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these rats. These results suggest that learning deficits in these animals are partly due to the 
impairment of neurotransmitter release. 
McDonald et al. (223) observed that single bilateral hippocampal injections of Aj3 1-
40 (2 nmol) impaired learning of a signaled footshock avoidance and a food reinforcing task 
in a Y-maze, suggesting a detrimental effect of Aj3 on memory consolidation. Chronic daily 
Aj3 1-40 injections (0.5 nmol/day) for 26 days had no effects on an eight-arm radial maze 
performance, and no aggregation of Aj3 or significant necrosis was observed upon 
postmortem histological analysis. These experiments suggest that single injections of Aj3 
impair memory consolidation but repeated injections do not affect well-learned behavior. In 
a follow-up study (224), these authors sought to determine if the amnesia was specific to 
the Aj3 1-40 sequence, and if the amnesia could be attributed to a consolidation process. 
The results indicate that the reverse peptide Aj3 40-1 has no behavioral effect, and that Aj3 
1-40 injected after partial training does not interfere with a consolidation process. 
Cleary et al. (41) showed that acute bilateral hippocampal Aj3 1-40 ( 1-3 nmol) 
administrations 20 min before testing did not alter the behavior of rats performing under 
stable food-maintained schedules of reinforcement or under a delayed conditional 
discrimination procedure. Also, no behavioral changes were observed during chronic 15 
days Aj3 1-40 ( 1 nmol/day) injections but lever-pressing performance declined significantly 
30 days after termination of the chronic daily regimen. Thioflavin S positive staining, 
indicating the presence of Aj3 deposits, was observed in 3 of 6 rats in and around the area 
of cannula termination approximately 60 days after the last Aj3 1-40 injection. 
Giovannelli et al. ( 102) demonstrated that unilateral injections of Aj3 1-40 (2. 3 nmol) 
and Aj3 25-35 (9.4 nmol) into the right nucleus basalis of rats resulted in Congo red positive 
Aj3 deposits at the injection site. These deposits were visible for about 21 days in the Aj3 
25-35 treated rats and for at least two months in the Aj3 1-40 injected rats. The presence 
of these deposits was associated with a reduction in the number of ChA T immunopositive 
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neurons in the A~ 25-35 rats at 7 and 14 days postoperatively, and in the A~ 1-40 rats at 
7, 14, 21, 30 and 60 days postinjection. This reduction in ChAT IR was paralleled by a 
decrease in basal acetylcholine release from the parietal cortex ipsilateral to the lesion. 
Disruption of object recognition was observed at 7 and 14 days after A~ 25-35 injection, 
whereas A~ 1-40 caused a slight impairment only two months after lesion. 
In addition to injections of A~ alone, a report by Dornan et al. (65) indicated that 
bilateral injections of 4 nmol of A~ 25-35 and 6 nmol of ibotenic acid into the rat 
hippocampus disrupted acquisition of spatial learning in the radial arm maze 8-32 days 
postinjection, whereas A~ 25-35 alone had no effect. Histological examination revealed that 
only the combination of A~ 25-35 with ibotenic acid produced a lesion along with focal 
deposits in the hippocampus. 
We observed that A~ 25-35 (1 or 8 nmol) injected bilaterally into the ventral 
pallidum/substantia innominata (VP/SI) of rats failed to produce behavioral, histological or 
neurochemical signs of toxicity (314). Also, neither dose of A~ 25-35 potentiated the 
effects of quinolinic acid (37 .5 nmol) on behavior or amygdaloid ChAT activity, and did not 
appear to increase the histological damage caused by quinolinic acid. These results suggest 
that A~ 25-35 is not neurotoxic within the VP/SI and that it does not potentiate the 
neurotoxicity of quinolinic acid in the VP/SI. 
All the above studies analyzed young animals and injected peptide sequences that 
correlate with the human A~. In one study by Winkler et al. (354), a rat A~ 1-42 was 
injected bilaterally into the hippocampus or the lateral ventricle of 3 month old rats. Fifteen 
months later, these rats did not differ from vehicle treated rats in their ability to learn a 
spatial memory task in the Morris water maze. A~ IR was detected at the injection site at 
16 months following injection but no qualitative neuronal loss was observed. 
In addition to these findings, behavioral effects have also been demonstrated for 
amylin, which is a 37 amino acid amyloidogenic peptide of a different sequence than A~. 
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Kovacs et al. (175) observed that a unilateral administration of amylin (64-255 pmol) into 
the lateral brain ventricle of rats led to an increase in the latency of passive avoidance 
behavior, and caused facilitation of the extinction of active avoidance behavior 24 h 
postinjection. Amylin also inhibited locomotion in an open field, and increased rearing and 
grooming activity during the first 24 h postinjection. According to the authors, these 
findings suggest that amylin influences the behavioral reaction in these paradigms mainly by 
acting on locomotion, and not by modifying learning and memory processes. 
Tau Protein 
The main component of neurofibrilllary tangles is paired helical filaments (168,335), 
which consist largely of the protein tau in an abnormal state of phosphorylation 
(171, 183,355,356). Tau consists of six isoforms of a molecular weight of 55 to 62kD that 
are generated by alternative splicing of a single gene (106, 140). Tau is a potent promoter 
of tubulin assembly in vitro (43), and is often associated with microtubules in neuronal 
axons. However, it is also found normally in the somatodendritic compartments and in glia 
(201,232,259). In AD, neurofibrillary tangles are found predominantly in the perinuclear 
region encircling the nucleus (231), but prominent tau IR fibers without classical tangle 
formation are also found in cell bodies of affected neurons (259). There is a correlation 
between the number of cortical tangles and the degree of cognitive impairment (17,289), 
and it has been reported that tangles, but not senile plaques, parallel duration and severity 
of AD (8). Tau isolated from paired helical filaments is extensively phosphorylated 
compared to normal tau but there has also been isolated from AD brain abnormally 
phosphorylated non-paired helical filament tau (173). Presently, the kinases that mediate 
tau phosphorylation have not been conclusively identified but various kinases have -been 
15 
implicated (67, 151, 152, 194,260,341,345). There may also be alterations in the activities 
of certain protein phosphatases in AD (111, 185,215,266), that have been shown to 
dephosphorylate tau in vitro (66, 109, 110, 112,294,343). It should be noted, however, that 
the significance of the hyperphosphorylated state of tau to the etiology and progression of 
AD remains to be determined. Interestingly, intracerebral injection of abnormally 
phosphorylated tau proteins purified from AD brains has been shown to enhance A~ IR in rat 
brain (312), suggesting an association between plaque and tangle formation in AD. 
Various antibodies recognize tau proteins, such as tau-2 and Alz-50. The tau-2 
antibody recognizes tau proteins in both the phosphorylated and non-phosphorylated form. 
This antibody does not discriminate between normal tau and hyperphosphorylated 
Alzheimer's tau in unfixed tissue, but recognizes only the Alzheimer's tau in fixed tissue 
(259). The Alz-50 antibody in immunocytochemical studies stains AD brain tissue (55), but 
its IR in normal brain tissue appears to depend on the method used (293). It demonstrates 
early changes in AD by recognizing abnormally phosphorylated tau protein (337). 
Apolipoprotein E 
The gene for ApoE is located on chromosome 19 and is the first known gene that 
confers susceptibility for the sporadic late-onset form of AD. The three major alleles of 
ApoE are E2, E3, and E4. An increased frequency of the ApoE4 allele is associated with 
late-onset AD (325), and leads to an increased number of amyloid plaques compared to AD 
cases that do not have this risk factor (280,299). Conversely, the ApoE2 allele decreases 
the risk of AD and delays disease onset (49,290). ApoE binds to soluble A~ in vitro (326) 
and enhances fibrillogenesis in an isoform specific manner, with ApoE4 being more active 
than ApoE3 (205,296,359). These in vitro studies correlate with findings that ApoE is 
associated with amyloid plaques (245,246,280,360). ApoE is found }n the neuronal 
cytoplasm (125) and is also associated with neurofibrillary tangles in AD (245,280). It 
binds to nonphosphorylated tau in vitro, and ApoE3 binds with higher affinity than ApoE4 
(324). 
Presenilins 
Mutations in three genes account for a portion of cases of the early-onset familial 
form of AD. The first of these genes to be associated with AD was the gene for APP on 
chromosome 21 . However, mutations in this gene account only for a small fraction of the 
early-onset AD cases. The most common mutations are found on chromosome 14 
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(297, 322), in a gene that encodes the protein presenilin 1 (31 0). This protein appears to be 
an integral membrane protein containing seven to nine transmembrane domains. A second 
transmembrane protein, presenilin 2, is 67% homologous in amino acid sequence to 
presenilin 1 . The gene coding for presenilin 2 is found on chromosome 1 and is the likely 
genetic locus of familial AD in Volga German families (192, 193). More than 25 different 
inherited mutations have been identified in these two presenilin genes (344). The functions 
of the proteins encoded by the presenilins are unknown but they may be localized to the 
endoplasmic reticulum and Golgi complex in transfected cells ( 176). This finding suggests 
that the presenilins may affect protein transport and/or processing, possibly modulating the 
processing of APP and production of A~. In support of this scenario, a recent report 
indicates that levels of A~ 1-42 and/or A~ 1-43 are increased in fibroblast media and plasma 
from carriers of mutations in these genes (298). In addition, increased A~ 1-42 and/or A~ 
1-43 levels are found in brains of mice that express mutant presenilin 1 (69). 
Overexpression of presenilin 2 in PC 1 2 cells has been demonstrated to increase apoptosis 
induced by trophic factor withdrawal or AP, and a presenilin 2 mutation associated with 
familial AD enhances basal apoptotic activity (362). 
Glia in Alzheimer's Disease 
17 
More than half of the volume of the brain consists of non-neuronal cells (93). The 
largest class of these cells are comprised of neuroglia, and there are up to 1 0 times as many 
neuroglial cells in the brain as there are neurons. The neuroglia are further categorized as 
microglia or macroglia. 
Macroqlia: Astrocytes 
The majority of the neuroglia are macroglia which are further subdivided into 
oligodendrocytes and astrocytes. Astrocytes modulate inflammatory and immune responses 
in the CNS, induce and help maintain the blood-brain-barrier, regulate the neuronal 
environment, and facilitate neuronal growth, repair and regeneration. The transformation of 
resting astrocytes to reactive astrocytes is one of the earliest and most dominant responses 
of the CNS to tissue injury. The reactive state is characterized by nuclear changes and a 
cytoplasmic enlargement that is associated with the generation of thicker, longer and more 
complex processes. In the AD brain, reactive astrocytes are found in high abundance 
surrounding senile plaques (70, 126, 128,250). They colocalize with plaques at a relatively 
early stage in AD and apparently prior to the appearance of plaque associated dystrophic 
neurites (270). Glial fibrillary acidic protein (GFAP) (77) is a component of the glial 
intermediate filaments that form part of the cytoskeleton, and is found predominantly in 
astrocytes. GFAP levels in AD brains are increased 8 to 16 fold compared to control brains 
(21,60). 
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There are several possible roles for astrocytes in AD. Reactive astrocytosis may 
occur merely as a response to an underlying pathology. Astrocytes may be recruited in an 
attempt to attenuate the progression of the disease and/or to enclose degenerating areas 
with astrogliotic scar. Astrocytes may also have a causal or contributory role in the 
pathology. In this scenario, the primary pathology may be astrocytic and lead to AP 
production and/or subsequent events that lead to neuritic damage and tangle formation. 
Also, AP may be toxic to astrocytes and that may indirectly lead to neuronal damage. 
Recent reports suggest that AP induces reactive astrocytosis in vitro (34, 141,271), but 
does not decrease astrocyte viability (271 ). 
Excitotoxicity has been hypothesized to have a role in the pathology of AD ( 114). 
Glutamate is the major excitatory neurotransmitter in the brain, and the distribution of 
plaques in AD correlates well with the termination of glutamatergic fibers (79,264,283). 
Both astrocytes and neurons are involved in glutamate transport and metabolism. Glutamate 
uptake is primarily performed by astrocytes, both in culture and in vivo (135, 136, 142,229). 
AP in some culture systems has been observed to potentiate neuronal excitotoxicity 
(170,218). This suggests that the glutamate transporting activity of astrocytes may be 
impaired by AP but no reports have investigated this phenomenon. However, AP has been 
shown to increase expression of glutamine synthetase (GS) in cultured astrocytes, 
suggesting that AP-related reactive astrocytosis in AD may benefit local neurons by 
enhancing glial capacity to regulate levels of glutamate (272). Conversely, AP has been 
reported to produce a mild but significant impairment in GS activity in mixed cultures (127). 
Whether GS levels and activity are affected in AD is unclear (164,319). 
Microqlia 
Over the last decade several investigators have noted that the AD brain exhibits 
many classical markers of immune-mediated damage. Microglia are the brain's 
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representatives of the immune system and express many leukocyte surface antigens which 
are upregulated in AD (227). In AD, there is a vigorous activation of the classical, but not 
the alternative complement pathway (74, 75, 153, 154,225,226). AD lesions are easily 
revealed by antibodies to complement factor (C) 1 q, C3d, and C4d (225,226). All these 
antibodies recognize extracellular amyloid deposits, dystrophic neurites, neurophil threads, 
extracellular neurofibrillary tangles, and even some intraneuronal tangles. The components 
of the complement pathway may be partly derived from reactive microglia ( 1 23). It is not 
known what causes activation of the classical complement pathway in AD, but it is of 
interest that A~ can bind C1 q (304). This interaction activates the classical cascade in vitro 
(282), and enhances the cytotoxicity of A~ (304), likely by increasing A~ aggregation into a 
~-pleated sheet structure and by stabilizing preformed aggregates (348). In the AD brain, 
microglia are known to associate with plaques (122, 155,228). Microglia in culture 
scavenge A~ (5) and microglia-like phagocytes have a role in A~ clearance following 
intraventricular infusions of A~ (92). However, A~ can induce degeneration of cultured 
microglia (174). 
Cytokines are polypeptides with diverse actions on many cell types, and are 
particularly important as mediators of inflammation and regulation of cell growth and 
differentiation. The cytokines are generally classified into four groups; the interleukins, 
tumor necrosis factors, interferons, and growth factors. Inflammatory cytokines found in 
senile plaque regions include interleukin (IL) 1, IL-6, and tumor necrosis factor 
(62, 117,309). Microglia seems to be the major source of IL-1 within the CNS, but this 
cytokine is also found in astrocytes and neurons (300). In rat, mouse, human and other 
species, IL-1 exists in two forms, IL-1a (199) and IL-1 ~ (9), that are the products of two 
separate genes (40,97). Human IL-1 a and IL-1 ~ have 25% homology and appear to have a 
similar biological activity (63). IL-1 ~in vitro stimulates the APP promoter (64), induces APP 
mRNA (59,89, 108), stimulates APPs secretion (31 ), and enhances A~ cytotoxicity in PC12 
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cells (82). AP in vitro induces IL-1 P mRNA in astroglial cells (59), enhances astro- and 
microglial secretion of IL-1 (4), and stimulates the proliferation and morphological 
transformation of microglia (4). AP also increases nitric oxide production from microglial 
cells in culture but not from astrocytes or cortical neurons. This production is potentiated by 
the cytokine interferon-y and leads to an injury of cortical neurons (149). Furthermore, the 
synergistic activation of cultured microglia by AP and interferon-y causes the production of 
neurotoxic free radicals (230). 
Distribution of Alzheimer's Disease Pathology 
Individuals with Down's syndrome (trisomy 21) invariably develop the 
neuropathological hallmarks of AD (23, 187). Therefore, it is likely that the sequence of 
pathogenic alterations in Down's syndrome resembles that of AD. Overexpression of APP 
mRNA has been observed in Down's syndrome brains (248,291), and senile plaques appear 
at a younger age than do neurofibrillary tangles in Down's syndrome ( 100,212,291,358), 
suggesting that AP may have a role in tangle formation. In AD, the distribution of plaques 
and tangles suggests that neurons that have efferent projections to areas that contain 
amyloid deposits often contain tangles (265). For example, senile plaques accumulate 
within the amygdala in the terminal zone of tangle bearing hippocampal neurons ( 1 81). This 
suggests that AP may act on nerve terminals to cause cytoskeletal alterations in axons that 
ultimately lead to tangle formation within the perikarya (265). This notion is supported by 
the observation that the APP is predominantly located in the synaptic zone of neurons 
(301). Therefore, deposition of AP fibrils and their initial toxic effects would primarily occur 
near their site of generation, namely at the nerve terminals. These effects then would 
gradually spread to distal brain regions that send axons to the area of initial deposition. 
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However, there are areas severely affected by neurofibrillary tangles whose projection zone 
is not frequently affected by senile plaques (279). For example, subicular/CA 1 hippocampal 
neurons develop tangles and project strongly to layer IV of the entorhinal cortex, which 
contains tangles but few senile plaques ( 14 7). The pathological process in AD occurs over 
decades. It is possible that different regions and/or cell types of the brain have different 
kinetics for the development and/or degradation of neurofibrillary tangles and senile plaques. 
The major pathological changes in AD are in regions of the medial temporal lobe, 
including the hippocampus, amygdala, entorhinal cortex and parahippocampal gyrus (265). 
Within these brain regions, the number of senile plaques has been reported to be highest in 
the amygdala (8). Some reports indicate that the amygdala is affected earlier in the disease 
than the hippocampal or cortical areas (158,258). Severe ChAT deficits have been reported 
in the amygdala in cases of histopathologically confirmed AD with no significant deficits in 
the neocortex or hippocampus (258). Also, in at least one AD case report, senile plaques 
and neurofibrillary tangles were almost exclusively restricted to the amygdala ( 1 58). The 
presence of numerous senile plaques without neurofibrillary tangles in the amygdala of a 1 9 
year old patient with Down's syndrome suggests that the amygdala is a focus of early 
pathological changes in Down's syndrome and possibly AD (243). In patients with Down's 
syndrome between the ages of 35-45, many classic senile plaques are found in the 
amygdala but neocortical senile plaques are sparse and usually primitive, and neurofibrillary 
tangles are rare (208-210). A study (211) of non-demented patients of all ages showed the 
greatest severity of senile plaques primarily within the amygdala, whereas neurofibrillary 
tangles were found predominantly within the hippocampus. 
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Laterality in Alzheimer's Disease 
The human brain is asymmetric, as are the brains of other animals. Although the left 
hemisphere is significantly different in function from the right, there appears to be no 
structure or chemical constituent that is present in one hemisphere but not in the other. 
However, there are quantitative differences between the hemispheres that may lead to 
qualitative differences. Asymmetry has been observed in neurotransmitter, neuroendocrine, 
and neuroimmunologic activity (361 ). 
Some investigators have demonstrated lateralization in the involvement of the rat 
amygdala in learning and memory (15,45-47), and lesions of various brain regions in rats 
(36,61, 121, 184,262,281,329,342) and mice (10) have asymmetrical effects. Ligation of 
the right middle cerebral artery has been shown to lead to hyperactivity and reductions in 
norepinephrine and dopamine, whereas ligation of the left middle cerebral artery has no 
behavioral or neurochemical effects (281). Also, occlusion of the left or right middle 
cerebral artery has different effects on mean arterial pressure, renal sympathetic nerve 
discharge, and plasma norepinephrine levels ( 1 21). Suction lesions of the right frontal 
cerebral cortex induce hyperactivity (61,262), that is accompanied by a bilateral decrease in 
norepinephrine concentrations (262). However, identical lesions of the left cortex do not 
produce hyperactivity (61,262) or a decrease in norepinephrine concentrations (262). Left 
cortical ablations affect mainly the activity of serotonergic inputs to the right neocortex, 
whereas ablations of the right cortex influence the activity of the catecholaminergic inputs 
to the left cortex ( 10). Ablations of the prefrontal or parietal cortices lead to lateralized 
brain immunomodulation (342). Kainic acid injections into the right frontal cortex produce a 
significantly greater hyperactivity than identical injections into the left hemisphere ( 1 84). 
Striatal lesions with 6-hydroxydopamine lead to greater dopamine depletion in right-lesioned 
rats than in left-lesioned rats (329). Also, left and right 6-hydroxydopamine lesions of the 
23 
medial prefrontal cortex differentially alter subcortical dopamine utilization and the behavioral 
response to stress (36). 
Asymmetries have been observed in the histopathological hallmarks (52,235), and in 
the reductions in ChAT activity (235,287) in individual cases of AD, but preferential 
involvement of either hemisphere has not been demonstrated in groups of AD patients. 
Interestingly, asymmetry in the density of senile plaques diminishes with increasing 
neuropathological severity (235), suggesting that laterality may be more prominent in the 
initial stages of the disease. In AD, there is an extensive neuronal loss and shrinkage in all 
subdivisions of the amygdala (340), but no left-right hemispheric differences were detected 
in total neuron numbers in a study of 9 AD cases (340). However, hemispheric laterality in 
cerebral metabolism and perfusion in AD has been demonstrated in several studies. In most 
of these reports, there is no directional preference in asymmetry (37,68,95, 113, 129-
132,254), whereas some findings indicate preferential involvement of the left (197,306) or 
the right hemisphere (239). Early onset cases of AD have been associated with a greater 
prevalence of left (247,306) or right (148) hemispheric dysfunction compared to late onset 
AD cases. Other studies have found no correlation between asymmetry in hemispheric 
dysfunction and the duration or severity of the illness (197,239), suggesting that laterality in 
AD reflects subtypes more than the evolution of the disease. 
Animal Models for Alzheimer's Disease 
There is a loss of cholinergic neurons in the basal forebrain in AD, that contributes 
to the amnestic deficits observed in the disease (12,57,351 ). The early animal models of 
AD attempted to mimic the degeneration of the basal forebrain cholinergic neurons by 
lesioning the nucleus basalis magnocellularis (84, 134, 195) and/or the medial septal. area 
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( 1 34). This approach was limited as a model of AD because it lacked the broad spectrum of 
pathological features of the disease. Neurons producing norepinephrine, serotonin, 
dopamine, glutamate, y-aminobutyric acid, somatostatin, neuropeptide Y, corticotrophin 
releasing factor, substance P, and other neuromodulators are also affected in AD 
(54,56, 157, 177,288,327). Because of these broad deficits in neurotransmitter systems, it 
is unlikely that AD can be treated by transmitter replacement therapy alone. A more feasible 
approach is to develop compounds that interfere with neuritic plaque and tangle formation, 
the major histopathological hallmarks of the disease. 
The discovery of A~ as a major component of senile plaques and subsequent 
findings of its in vitro neurotoxicity led to model approaches examining the direct effects of 
A~ in vivo by microinjection of A~ into the brains of rats and monkeys (see A~ Peptides and 
Effects of A~ Peptides on Behavior). The reproducibility of A~ toxicity in vivo has been 
inconsistent (42,91,99, 101, 102, 178, 180,314,320,354). This may be due to variations in: 
1) the conformational state (25,269,273), dose, and sequence of A~; 2) method of 
administration; 3) pathological endpoints measured; 4) what brain region and/or hemisphere 
is injected; 5) postoperative interval; and, 6) species and/or strain used. Therefore, further 
studies on the in vivo effects of A~ are warranted. 
Various transgenic approaches toward an animal model for AD have recently been 
described. The approaches differ in several aspects such as: 1) in the selection of a 
promoter to drive APP expression; 2) in the isoform or segment of APP expressed; 3) in the 
strain of mouse used; and, 4) in the age of the animals at the time of behavioral testing 
and/or histological analysis. 
AB Transgene: Overexpression of mouse A~ in mice by LaFerla et al. (186) resulted in 
extensive neuronal apoptotic degeneration and reactive astrogliosis without any evidence of 
amyloid deposition or neurofibrillary pathology. The mouse A~ was selected in case an 
interaction with species specific factors was required for its toxicity. These animals had 
approximately half the lifespan of normal mice and some of them developed seizures. 
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APP Transqenes: Approaches using full length mouse or human APP can be divided into 
three groups: 1) expression of normal individual APP isoforms; 2) expression of individual or 
several APP isoforms that carry mutations that have been associated with AD; and, 3) 
generation of mice transgenic for the intact APP gene. 
The initial report on behavioral impairments in transgenic APP mice by Yamaguchi et 
al. (364) demonstrated that mice expressing the normal human APP695 isoform had 
impaired spatial memory in the Morris water maze. Training commenced when the mice 
were 8 weeks old and behavioral testing continued until the animals were 20 weeks old at 
which time they were sacrificed for histological analysis. These animals were significantly 
retarded in initial learning and in learning a new escape location, but they eventually reached 
control levels. However, these mice also had slower swimming speed and reduced 
nocturnal activity, that may have contributed to their deficit in spatial learning. No A~ 
deposits were observed in these mice, and no neuropathological hallmarks of AD have been 
detected in this same transgenic line at 1-3 years of age. The authors suggest that gene 
dosage effect of APP695 may account for the memory impairment. The authors also raise 
the question of whether insertion of multiple copies of any gene construct may impair 
cognitive function, because inheritance of relatively small amounts of extra genomic DNA in 
human imbalanced translocation karotypes results in mental retardation. 
Czech et al. (53) showed that transgenic mice containing the three major neuronal 
isoforms for the normal human APP, that is APP695, APP751, and APP770, expressed the 
transgenic APP in several tissues including brain but expression levels never exceeded those 
of the endogenous mouse APP (53). No pathological changes resembling those of AD and 
Down's syndrome were observed in these animals. However, the mice transgenic for 
APP695 showed an impairment in a spatial navigation task, and the mice transgenic for 
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APP751 showed deficits in motor performance. The authors of this study stress that it is 
not clear whether these behavioral effects are due to the expression of the transgene or to 
position effect of transgene integration. 
Hsiao et al. ( 146) demonstrated that transgenic mice overexpressing normal human 
or mouse APP695 died usually within a year and developed a CNS disorder that included 
neophobia and impaired spatial alternation, with diminished glucose utilization and 
astrogliosis mainly in the cerebrum. Human APP transgenes induced death much earlier 
than mouse APP transgenes expressed at similar levels. No extracellular amyloid was 
detected, indicating that some deleterious processes related to APP overexpression are 
dissociated from formation of amyloid. 
Transgenic mice expressing normal human APP751 have been shown by Higgins et 
al. (137, 138) and Quon et al. (277) to develop diffuse AP deposits and rarely an induction in 
Alz-50 IR, particularly in the hippocampus, cortex, and amygdala. The AP deposits were not 
Congo red positive and lacked neuritic involvement. Because the deposits did not show 
birefringence under polarized light when stained with Congo red, they did not have the P-
pleated sheet structure of AP that is found in senile plaques. These histopathological 
changes increased somewhat in frequency with aging (139). These mice also exhibited age 
dependent deficits in spatial learning in a water maze task and in working memory in 
spontaneous alternation in a Y maze (236). Interestingly, these transgenic mice also 
exhibited a greater latency in locating a visible platform in the water maze. This suggests 
that vision impairment may account for differences in performance. These deficits were 
mild or absent in 6 month old mice but were severe in 12 month old mice compared to age-
matched wild-type control mice. Neither age group of the transgenic APP751 mice showed 
any changes in string test, rotarod, plus maze, or circadian variation in spontaneous activity. 
These findings show that these mice did not have any gross motor, physiological or 
behavioral impairments that may have confounded interpretation of the learning tasks. 
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These mice may model the progressive learning and memory impairment that is a cardinal 
feature of AD, but further tests are necessary to investigate possible vision impairments. 
The discovery of the association of AD with inherited APP mutations led to the 
development of transgenic mouse models containing these mutations. Malherbe et al. (206) 
reported that transgenic mice expressing various familial AD missense mutations, that were 
maximally 1.3 fold of those of wild-type mouse APP, showed no AD-like pathology and had 
no behavioral impairments. However, recently two mouse models have been described by 
Games et al. (98) and Hsiao et al. (145), that contained age dependent compact congophilic 
A~ plaques similar to those observed in AD, and in one of these models these changes were 
associated with behavioral impairments (145). The first of these models to be described 
overexpressed APP containing the APP717 mutation that is associated with familial AD 
(98). These mice expressed 8-1 0 fold the normal level of APP and had large numbers of 
amyloid plaques in the hippocampus, corpus callosum, and cerebral cortex that first 
appeared at 6-9 months of age. The majority of the plaques were associated with reactive 
astrocytes and dystrophic neurites. The neocortices of these mice exhibited diffuse synaptic 
and dendritic loss, and contained diffusely activated microglia. This histopathology was 
region specific and age dependent as in AD, despite expression of the APP transgene 
throughout the brain. These results suggest that region and/or cell type specific 
vulnerability of the aging brain may dictate the pattern of plaque formation. A significant 
limitation of this model is the lack of neurofibrillary tangles, and their absence may reflect 
species variations in neuronal response to injury. Also, in this model there have been no 
reports of behavioral impairments associated with the histopathological changes. 
The other promising transgenic mouse model (145) overexpressed a mutated form of 
APP695, that has been found in a Swedish family with early-onset AD (242). These mice 
expressed this human form at 5-6 fold the levels of endogenous mouse APP, that remained 
unchanged between 2 and 14 months of age. These mice demonstrated normal learning 
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and memory in the Morris water maze and the Y maze at 3 months of age but were impaired 
by 9 to 10 months of age. A five fold increase in A~ 1-40 and a 14 fold increase in A~ 1-
42 was associated with these behavioral deficits. Numerous Congo red positive A~ plaques 
were present in mice with elevated A~ levels. The distribution of the histopathological 
changes was reportedly similar to that observed by Games et al. (98). Although the authors 
indirectly control for impairments in motor performance, it is possible that the behavioral 
impairments may be caused by visual impairments. This possibility, overlooked by the 
investigators, is based on the impairment of the transgenic mice in swimming to a visible 
platform. 
In contrast to other APP transgenic models, the expression of human APP variants in 
these two promising models (98, 145) substantially exceeds those of the endogenous mouse 
APP gene. Because of the various proposed roles for APP, it is likely that 5-10 fold increase 
in APP has several biological effects besides causing an increase in A~ production and 
subsequent plaque formation. It is also possible that insertion of multiple copies of any 
gene construct may impair cognitive function, because inheritance of relatively small 
amounts of extra genomic DNA in human imbalanced translocation karotypes results in 
mental retardation. The behavioral effects may also be due to position effect of transgene 
integration that may interfere with the expression of other genes. 
The complete human APP gene has also recently been introduced into mice by Lamb 
et al. (188) and Pearson et al. (263). Both sets of mice properly spliced human APP mRNA 
in their brains to generate the three major isoforms of APP, APP695, APP751, and APP770, 
but in hemizygotes their expression levels were below those of the endogenous mouse APP. 
No signs of AD-type pathology has been observed (188) or reported (263) in these mice. 
These mice may overexpress human APP once they have been bred to homozygosity. 
Even though several in vitro studies have tested various hypotheses for the 
mechanism by which A~ exerts its toxic effect, these hypotheses have not been adequately 
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assessed in in vivo situations. It is important to continue to explore the in vivo effects of 
AP by direct injections into brain. Findings from these studies may help elucidate the 
sequence of pathogenic events that ultimately lead to AD. They may also distinguish 
between the biological effects of AP and elevated levels of APP, respectively. There are 
several advantages associated with the injection approach. For example, it is substantially 
less expensive. The pathology appears to peak at an earlier timepoint than in transgenic 
animals, thereby reducing the time required for drug screening. Furthermore, the pathology 
is due to AP, but in the transgenic animals some of the pathology may be due to effects of 
elevated levels of APP and/or due to position effect of transgene integration. For example, 
the site of transgene integration is thought to be random and its location may affect the 
expression of other genes. Therefore, injection models may give a clearer picture than 
transgenic models of the role of AP in the progression of AD. 
CHAPTER II 
AIMS OF THE PRESENT STUDY 
Puroose 
Because the early and primary histopathological changes in Alzheimer's disease (AD) 
are predominantly found in temporal lobe structures, it was determined if injections of 
amyloid-P (Ap) 25-35 into the amygdala of the rat can induce the appearance of abnormal 
conformations of tau proteins and reactive astrocytes as seen in AD. It also was examined 
whether the effects of AP were time dependent and included neuronal shrinkage, cell loss 
and/or microglial activation. Finally, it was determined whether the histological effects of 
AP were associated with alterations in choline acetyltransferase (ChAT) activity and/or 
behavioral changes. Thus, the overall objective of this project was to develop an animal 
model for AD. 
Overall Hypothesis: In vivo injections of AP will induce the appearance of abnormal 
conformations of tau proteins and reactive astrocytes as seen in AD. The effects of AP will 
be time dependent and include neuronal shrinkage, neuronal loss and microglial activation. 
Furthermore, these histological changes will be associated with neurochemical and 
behavioral alterations. 
Specific Aim 1: To determine the histological effects of unilateral intra-amygdaloid injections 
of AP 25-35 (5.0 nmol) in young rats at 8 and 32 days postoperatively. 
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Hypothesis: A~ will induce conformational changes in tau proteins. These changes will be 
associated with reactive astrocytosis, neuronal shrinkage and cell loss. 
Methods: Cresyl violet, tau-2, Alz-50 and GFAP staining 
Rationale: 
The histopathological characteristics of AD include neurofibrillary tangles, senile 
plaques, reactive astrocytes, neuronal shrinkage, and cell loss in several brain regions. The 
main component of the neurofibrillary tangles is paired helical filaments ( 168,335), which 
consist largely of the microtubule associated protein tau in an abnormal state of 
phosphorylation (171, 183,355,356). In the AD brain, reactive astrocytes are associated 
with senile plaques (70, 126, 128,250). Senile plaques consist predominantly of A~ 1-42 
peptide ( 103,214,233,285), which is derived from a large membrane spanning protein, the 
amyloid-~ precursor protein (APP) (166). Mutations in APP in some forms of familial AD are 
associated with an elevated production of A~ (33,39,331 ). APP is overexpressed in 
Down's syndrome (248,291 ), and individuals with this disease invariably develop the 
neuropathological hallmarks of AD (23, 1 87). The proposed role for A~ in the pathogenesis 
of AD is further supported by the neurotoxicity of A~ in vitro (369,370), which includes 
amino acids 25-35 of the peptide (370). 
The reproducibility of A~ toxicity in vivo has been inconsistent 
(42,91,99, 101, 102, 178, 180,314,320,354). This may be due to variations in: 1) the 
conformational state (25,269,273), dose, and sequence of A~; 2) method of administration; 
3) pathological endpoints measured; 4) what brain region and/or hemisphere is injected; 5) 
postoperative interval; and, 6) species and/or strain used. Therefore, further studies on the 
in vivo effects of A~ are warranted. 
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Recently a direct association between plaque and tangle formation in AD has been 
demonstrated by a few studies. In vitro studies have demonstrc~ted that AP increases tau 
protein kinase I (TPK I) activity (332), induces abnormal tau immunoreactivity (IR) (26,207), 
and that the neuronal death caused by AP can be prevented with TPK I antisense 
oligonucleotides (332). These findings suggest an association between plaque and tangle 
formation in AD. A few in vivo studies have investigated the effects of AP injected into the 
central nervous system on tau IR (42,91,99, 178, 180,274). Some of these studies indicate 
that AP can induce the appearance of abnormal tau proteins in the vicinity of the injection 
site (rat cerebral cortex and hippocampus) (91, 178, 180). Other studies have failed to show 
any effect (42,99,274). For the most part, these in vivo studies have only been qualitative 
or descriptive in nature. No attempts have been made to quantify AP induced effects by 
counting neuronal tau IR cells. 
AP has been shown to increase intracellular calcium (7,218). Calcium influx in 
cultured rat hippocampal neurons caused by glutamate or a calcium ionophore induces tau 
IR as recognized by the antibodies Alz-50 and 5E2 (216). Protein kinases are generally 
activated by increases in intracellular calcium and several of those have been shown to 
phosphorylate different sites on tau proteins (238). Therefore, AP may increase the 
phosphorylation of tau proteins through an activation of kinases mediated by an increase in 
intracellular calcium. The activities of some phosphatases that may dephosphorylate tau 
proteins have been shown to be decreased in AD (111,311 ). Therefore, AP 25-35 may also 
be decreasing the dephosphorylation of tau proteins through an inhibition of phosphatases. 
Because of the proposed role for AP in the pathogenesis of AD, intracerebral 
injections of AP may induce the pathological changes that occur in AD. It can be argued 
that because AP 1-42 is the most prevalent form of AP in senile plaques, it is appropriate to 
use that peptide for injections into brain instead of AP 25-35. However, the main problem 
with using AP 1-42 is its insolubility in physiological solvents. Therefore, there is a risk of 
potentially toxic solvents interfering with the properties and effects of A~ 1-42. On the 
other hand, A~ 25-35 is readily soluble in H20 and acquires the same ~-pleated sheet 
conformation as A~ 1-42, which is the toxic conformation of A~. 
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The amygdala was chosen as a region for A~ injections because it may be affected 
earlier in AD than hippocampal or cortical areas (158,258). The major pathological changes 
in AD are in regions of the medial temporal lobe, including the hippocampus, amygdala, 
entorhinal cortex and parahippocampal gyrus (265). Within these brain regions, the number 
of senile plaques has been reported to be highest in the amygdala (8). Individuals with 
Down's syndrome invariably develop the neuropathological hallmarks of AD (23, 1 87). The 
presence of numerous senile plaques without neurofibrillary tangles in the amygdala of a 1 9 
year old patient with Down's syndrome suggests that the amygdala is a focus of early 
pathological changes in Down's syndrome and possibly AD (243). In patients with Down's 
syndrome between the ages of 35-45 many classic senile plaques are found in the amygdala 
but neocortical senile plaques are sparse and usually primitive, and neurofibrillary tangles are 
rare (208-210). There have been no previous reports on in vivo injections of A~ into the 
amygdala. 
Unilateral injections were employed to determine if A~ induces histopathological 
alterations both ipsi- and contralaterally. The time of sacrifice (8 and 32 days) and the dose 
of A~ (5.0 nmol) were chosen because preliminary results in our laboratory indicated that 
these parameters were associated with tau IR adjacent to the injection site in the median 
raphe nucleus. Neuronal shrinkage and neuronal loss are one of the hallmarks of AD. 
Cresyl violet staining was used in the present study to observe these histological changes. 
The tau-2 antibody reacts exclusively with tau proteins in both the phosphorylated and non-
phosphorylated form. This antibody does not discriminate between normal tau and 
hyperphosphorylated Alzheimer's tau in unfixed tissue, but recognizes only the Alzheimer's 
tau in fixed tissue (259), and was therefore used in the present experiment. The Alz-50 
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antibody was also used to detect AD-like tau proteins. Alz-50 stains AD brain tissue (55), 
but its IR in normal brain appears to depend on the method used (293). It demonstrates 
early changes in AD by recognizing abnormally phosphorylated tau protein (337). Although 
the epitope that Alz-50 recognizes may not be phosphorylated, the overall peptide 
conformation recognized by the antibody may be phosphorylation dependent 
(105, 182,337). 
Using one antibody that recognizes abnormal tau proteins is not sufficient to 
determine if AP can induce the appearance of AD-like tau proteins. The temporal sequence 
leading to abnormal phosphorylation and/or conformational changes in tau proteins is not 
known. It is possible that AP may be inducing early changes in tau proteins that are not 
detected by both the tau-2 and Alz-50 antibodies. These two antibodies recognize different 
conformation dependent epitopes on tau proteins. AP may be inducing multiple 
conformational changes in tau proteins, which are differently stained using these two 
antibodies. The nature and extent of these conformational changes may be time dependent, 
brain region specific, and differ within the neuronal structure. 
GFAP (77) is a component of the glial intermediate filaments that form part of the 
cytoskeleton, and is found predominantly in astrocytes. GFAP levels in AD brain are 
increased 8 to 1 6 fold compared to control brains (21, 60). Staining with an antibody 
against GFAP was performed to determine 1) if AP increases the appearance of reactive 
astrocytes, as seen surrounding senile plaques in AD, and 2) if there appears to be a 
correlation between the location and severity of tau-2 and GFAP IR. 
Specific Aim 2: To determine the histological effects of bilateral intra-amygdaloid injections 
of AP at 8, 32, 64, 96 and 128 days postoperatively. 
Hypotheses: 1) The histological effects of AP will increase with time; and, 2) will be 
potentiated by bilateral administration due to the inability of the intact side to compensate 
for the contralateral insult. 
Methods: Cresyl violet, Congo red, tau-2, GFAP and IL-1 p staining. 
Rationale: 
The overall objective of this project was to develop an animal model for AD. 
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Therefore, it was necessary to know how long the effects of AP lasted to prepare for 
screening of drugs that prevent, reduce or reverse the histopathological effects of AP. AD 
is a bilateral disorder and bilateral infusions are required to determine if the effects of AP are 
exponential and for behavioral analyses. To prepare for behavioral experiments, it was 
necessary to perform a time course study on the histological effects of AP. The detrimental 
effects had to last throughout the behavioral experiments, which typically are performed 4-6 
weeks postoperatively. Congo red staining was performed to determine if the AP deposits 
within the rat amygdala were of the p-pleated sheet structure that is observed in senile 
plaques in AD. Microglia appear to be the major source of IL-1 within the CNS (300). In 
the AD brain, microglia are known to associate with plaques (122, 155,228), and 
inflammatory cytokines found in senile plaque regions include IL-1 p (62). Thus, staining 
was performed on brain sections with an IL-1 p antibody to determine if the intra-amygdaloid 
AP deposits were associated with microglia. 
Specific Aim 3: To determine if bilateral intra-amygdaloid injections of AP affect ChAT 
activity within the amygdala at 32 days postoperatively. 
Hypothesis: AP injected into the amygdala reduces ChAT activity within the amygdala. 
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Methods: Measurements of ChAT activity. 
Rationale: 
The amygdala receives a prominent cholinergic input from the nucleus basalis 
(35,363), and ChAT activity has been reported to be severely reduced within the amygdala 
in AD patients (258,287,288). Measurements of amygdaloid ChAT activity were performed 
to investigate if the cytoskeletal changes and neuronal shrinkage within the amygdala were 
associated with a reduction in ChA T activity. The time of sacrifice was based on the results 
of the time course study that indicated that the histological effects of AP peak at 32 days 
postoperatively. Although neuronal loss may not be severe following intra-amygdaloid 
injections of AP, this compound may affect the metabolic integrity of cholinergic neurons 
projecting to the amygdala. The neurochemical changes in AD that best correlate with the 
severity of dementia are reductions in ChA T activity in temporal lobe structures (268). 
Thus, ChAT activity was measured within the amygdala. 
Specific Aim 4: To determine if bilateral intra-amygdaloid injections of AP cause behavioral 
changes that may simulate those observed in AD. 
Hypothesis: Bilateral intra-amygdaloid injections of AP will cause behavioral changes at 34-
52 days postoperatively, that may simulate those observed in AD. 
Methods: Open field, one-way active avoidance and Morris water maze. 
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Rationale: 
Electrolytic lesions of the amygdaloid complex (51,73, 163,305), lesions of the 
central nucleus (118, 160,350), or of the lateral and basal nuclei of the amygdala (159) 
enhance exploratory behavior of rats in the open field test. Furthermore, lesions of the 
amygdala have been shown to be associated with behavioral impairments in active 
avoidance learning (30,286), but do not appear to impair spatial learning in the Morris water 
maze (58,330). Lesions of the hippocampus severely disrupt spatial learning (257,278), 
and this impairment has been shown to be potentiated by amygdaloid lesions (1,267). 
Therefore, because intra-amygdaloid injections of A~ induced histopathological changes not 
only within the amygdala but also within the hippocampus, it was considered appropriate to 
use the water maze test. The time interval for behavioral testing (34-52 days 
postoperatively) was based on the severity of the histological effects observed in the time 
course study. 
CHAPTER Ill 
LOCAL AND DISTANT HISTOPATHOLOGICAL EFFECTS OF UNILATERAL INJECTIONS OF 
AMYLOID-~ 25-35 INTO THE AMYGDALA OF YOUNG MALE FISCHER RATS 
Abstract 
To determine if amyloid-~ (A~) induces tau-immunoreactivity (IR) and reactive 
astrocytosis in vivo, we injected A~ 25-35 (5.0 nmol) into the right amygdala of rats. At 8 
days postinjection, the peptide induced tau-2 IR in neuronal cell bodies and processes 
ipsilaterally in the amygdala, cingulate cortex and hippocampus. At 32 days postinjection, 
the intensity of tau-2 IR was greater than at 8 days in the amygdala and hippocampus, but 
not in the cingulate cortex. Induction of Alz-50 IR also was progressive but the morphology 
and distribution was different from tau-2 IR. Beaded fibers with occasional neuronal 
perikarya were visualized with Alz-50, and the IR was primarily observed in the ipsilateral 
amygdala. In addition, amygdaloid injections of A~ 25-35 induced reactive astrocytosis, 
particularly in the ipsilateral hippocampus at 32 days postoperatively. 
To our knowledge, this is the first study to show that in vivo injections of A~ 25-35 
induce progressive transsynaptic cytoskeletal and astrogliotic reactions, that gradually 
spread from the area of injection to brain regions that have prominent efferent connections 
with the injected area. These findings also suggest a direct association between plaque and 
tangle formation in Alzheimer's disease. 
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Introduction 
Alzheimer's disease (AD) is characterized histopathologically by amyloid deposition 
(senile plaques), neurofibrillary tangles and neuronal cell loss in several, but not all cortical 
and subcortical regions. The main component of senile plaques is the amyloid-P (AP) 
peptide (103,214,233,285). It is derived from a large transmembrane protein, the amyloid-
p precursor protein (APP) ( 1 66) and is thought to play an important role in the pathogenesis 
of AD. Mutations in the APP gene on chromosome 21 are associated with a subpopulation 
of familial AD patients ( 1 04). The main component of neurofibrillary tangles is paired helical 
filaments (168,335), which consist largely of the microtubule associated protein tau in an 
abnormal state of phosphorylation (171, 183,355,356). 
In AD, the distribution of plaques and tangles within subcortical nuclei suggests that 
neurons that have efferent projections to areas that contain amyloid deposits often contain 
tangles (265). Therefore, since diffuse AP deposition precedes the development of 
neurofibrillary pathology ( 1 79), it has been hypothesized that AP acts on nerve terminals to 
cause cytoskeletal alterations in axons that ultimately lead to tangle formation within the 
perikarya (265). Individuals with Down's syndrome (trisomy 21) invariably develop a 
neuropathology indistinguishable from AD (23, 187). Therefore, it is likely that the sequence 
of pathogenic alterations in Down's syndrome resembles that of AD. Researchers have 
noted that senile plaques appear at a younger age than do neurofibrillary tangles in Down's 
syndrome (100,212,291,358), suggesting that AP may have a role in tangle formation. 
In vitro studies indicate that AP has neurotrophic (353,370) as well as neurotoxic 
(369,370) properties. The in vitro neurotoxic activity includes amino acids 25-35 of the 
peptide (370). The reproducibility of AP toxicity in vivo has been inconsistent 
(42,91,99, 101, 102, 178, 180, 191,274,314,320,354). This may be due to variations in the 
conformational state of AP (25,269,273), different biochemical and/or pathological 
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endpoints measured. In vitro studies have demonstrated that A~ increases tau protein 
kinase I (TPK I) activity (332), induces abnormal tau immunoreactivity (IR) (26,207), and 
that the neuronal death caused by A~ can be prevented with TPK I antisense 
oligonucleotides (332). There have been a few in vivo studies investigating the effects of 
A~ injected into the central nervous system (CNS) on tau IR (42,91,99, 178, 180,274). 
Some of these studies indicate that A~ can induce the appearance of abnormal tau proteins 
in the vicinity of the injection site (rat cerebral cortex and hippocampus) (91, 178, 180). 
Other studies have failed to show any effect (42,99,274). For the most part, these in vivo 
studies have only been qualitative or descriptive in nature regarding effects on tau IR. No 
attempts have been made to quantify A~ induced effects by counting neuronal tau IR cells. 
In the AD brain, reactive astrocytes are found in high abundance surrounding senile 
plaques (70, 126, 128,250). Glial fibrillary acidic protein (GFAP) is a component of the glial 
intermediate filaments that are found in the cytoplasm of astrocytes and form part of the 
cytoskeleton. GFAP levels in AD brains are increased 8 to 16 fold compared to control 
brains (21,60). A~ has been shown to induce a reactive phenotype in cultured astrocytes 
but does not decrease astrocyte viability (271 ). 
The major pathological changes in AD are in regions of the medial temporal lobe, 
including the hippocampus, amygdala, entorhinal cortex and parahippocampal gyrus (265). 
Some reports indicate that the amygdala is affected earlier in the disease than the 
hippocampal or cortical areas ( 1 58,258). Severe choline acetyltransferase (ChAT) deficits 
have been reported in the amygdala in cases of histopathologically confirmed AD with no 
significant deficits in the neocortex or hippocampus (258). Also, in at least one AD case 
report, senile plaques and neurofibrillary tangles were almost exclusively restricted to the 
amygdala ( 1 58). The presence of numerous senile plaques without neurofibrillary tangles in 
the amygdala of a 1 9 year old patient with Down's syndrome suggests that the amygdala is 
a focus of early pathological change in Down's syndrome and possibly AD (243). In 
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patients with Down's syndrome between the ages of 35-45 many classic senile plaques are 
found in the amygdala but neocortical senile plaques are sparse and usually primitive, and 
neurofibrillary tangles are rare (208-210). A study of non-demented patients of all ages 
showed the greatest severity of senile plaques primarily within the amygdala, whereas 
neurofibrillary tangles were found predominantly within the hippocampus (211). 
Because the primary and early histopathological changes in AD are found primarily 
within temporal lobe structures, we determined if a unilateral A~ 25-35 injection into the 
amygdala of the rat can induce the appearance of abnormal microtubule associated protein 
tau and reactive astrocytes as seen in AD. Secondly, we examined whether brain areas that 
project to and/or receive projections from the amygdala showed similar changes, and how 
long these effects last. 
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Materials and Methods 
Animals 
Male Fischer-344 rats were obtained from Harlan Sprague-Dawley Inc. (Indianapolis, 
IN). At the time of arrival, the rats weighed 250-300 g and were 3-4 months of age. The 
animals were housed individually, maintained on a 12 h light-dark cycle (lights on at 07:00 
h) in a AAALAC approved facility, had access to food and water ad libitum, and were 
habituated to their new environment for 2-3 weeks prior to surgery. 
Surgery 
Surgery was performed under sodium pentobarbital (50 mg/kg, intraperitoneally 
(i.p.); Butler, Columbus, OH) anesthesia. Atropine sulfate (0.4 mg/kg; Sigma, St. Louis, 
MO) and ampicillin sodium salt (50 mg/kg; Sigma) were injected intramuscularly once the 
animals were anesthetized. The animals received a unilateral injection into the right 
amygdala. A Kopf stereotaxic instrument was used with the incisor bar set at 3.3 mm 
below the interaural line. Injection coordinates measured from bregma and the surface of 
the skull (AP - 3.0, ML - 4.6, DV - 8.8) were empirically determined based on the atlas of 
Paxinos and Watson (261). The anteroposterior (AP) coordinate was positioned where the 
amygdaloid structure is largest. The mediolateral (ML) coordinate was centered between the 
medial and lateral aspects of the amygdala (medial to the basolateral nucleus). The 
dorsoventral (DV) coordinate was centered between the dorsal and ventral aspects of the 
amygdala. A volume of 3.0 µI was administered over 6 min (flow rate 0.5 µI/min) using a 
CMA/100 microsyringe pump (Carnegie Medicin AD, Solna, Sweden). The cannula was left 
in situ for 2 min following injection, and then was slowly withdrawn. Following surgery the 
animals were placed on a heating pad until they regained their righting reflex. 
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Most of the previous studies which have injected A~ into the brain have utilized a 
volume of 1.0 µI or less. The choice of an appropriate volume must be based on the 
physiochemical properties of the substance, outside and within the brain. It has been 
reported that A~ 25-35 at high concentrations (10 nmol/µI) forms a viscous gel (292), and 
may therefore adhere to the cannula resulting in an inaccurate dose delivery and spread of 
the peptide along the cannula track. In addition, A~ 25-35 appears to aggregate at the site 
of injection and does not diffuse from the vicinity of the injection site. For these reasons, 
we deemed it appropriate to inject a larger volume (3.0 µI). 
A~ 25-35 and A~ 35-25 (SACHEM, Torrance, CA) were supplied as a trifluoroacetic 
acid (TFA) salt with the peptide content 84.4 and 82.15 ( ± 3%), respectively. According 
to a representative at BACHEM there is no direct stoichiometric relationship between the 
content of A~ 25-35 and TFA. In order to not underestimate the amount of TFA, we 
assumed that it was 1 5. 6 % of the weight of the salt. Therefore, there are approximately 2 
nmol of TFA for each 1 nmol of A~ 25-35. The peptide and its respective vehicle (VEH; 
TFA, sodium salt; Sigma) were dissolved in Nanopure® H20 (H 20) immediately before use 
and stored at 4°C between injections. The reverse peptide was handled in the same 
manner. 
Animal Sacrifice and Tissue Preparation 
Animals were anesthetized with sodium pentobarbital (100 mg/kg, i.p.) and perfused 
transaortically at 8 or 32 days postoperatively with 250 ml of 0.1 M sodium/potassium 
phosphate buffer (PB, pH 7.4), followed by 500 ml of 4% paraformaldehyde in PB at a rate 
of 500 ml/h at room temperature. Immediately after beginning the perfusion, 1 .0 U/g 
heparin (Upjohn, Kalamazoo, Ml) was administered transaortically. Following perfusion the 
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brain was placed in the buffered fixative with 20% sucrose for 1.0 h. The brain was then 
trimmed into a 6 mm block surrounding the injection site, and stored in a solution containing 
20% sucrose, 0.1 % sodium azide and 0.01 % bacitracin in PB for 24 hat 4°C. The tissue 
block was then transferred to a solution containing 20% glycerol and 2% dimethyl sulfoxide 
dissolved in 0.1 M sodium phosphate buffer, and stored at 4°C until it was sectioned. 
Serial coronal sections (40 µm) were cut and five series of sections at 0.2 mm intervals 
were obtained for histological analysis using 1) cresyl violet, 2) tau-2, 3) Alz-50, and 4) 
GFAP. The first series was immediately mounted on slides, dried, and stained with cresyl 
violet. The other series were placed in an ethylene glycol cryoprotectant and stored at -
20°C until used for immunohistochemistry. 
Histology 
1) Cresyl violet: The mounted sections (40 µm) from one series were defatted in 
xylene and hydrated using ethyl alcohol and H20. Staining was performed for 20 min in a 
solution containing 200 ml of 0.2 M acetic acid, 133 ml 0.2 M sodium acetate and 67 ml of 
0.1 % cresyl violet acetate. The sections then were dehydrated in an ethyl alcohol series 
and cleared in xylene. The tissue was subsequently coverslipped using DePeX mounting 
medium. 
2) Tau-2: A series of 40 µm sections were removed from the cryoprotectant and 
washed overnight in phosphate buffered saline (PBS; pH 7.4) at 4°C. Sections were 
subsequently placed in 0.3% H20 2 in Tris buffered saline (TBS; pH 7 .6) for 30 min, and 
then washed 3 x 10 min in 0.3% Triton X-100 in TBS. The sections then were incubated in 
primary antibody tau-2 (Sigma) at a 1: 500 dilution for 24 h at room temperature. The 
antibody diluent contained 2.0% Triton X-100, 0.1 % sodium azide, 0.01 % bacitracin, 2% 
bovine serum albumin, and 10% normal horse serum in TBS. Subsequently, the tissue was 
washed 3 x 1 O min in 0.3% Triton X-100 in PBS, and then incubated for 1.0 h in 
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biotinylated anti-mouse immunoglobulin (lg) G secondary antibody (Vectastain ABC Elite kit, 
Vector Laboratories, Burlingame, CA) diluted 1 :2000 in 0.3% Triton X-100 in PBS. 
Following two washes in 0.3% Triton X-100 in PBS for a total of 15 min, the tissue then 
was incubated for 1 .0 h in avidin horseradish peroxidase (Vector) diluted 1 :2000 in 0.3% 
Triton X-100 in PBS. The sections were washed in PBS for 1 .0 h, and sodium acetate 
buffer (0.2 M, pH 6.0) for 15 min, and then reacted in 3,3'-diaminobenzidine 
tetrahydrochloride (DAB) with nickel ammonium sulfate intensification (35 mg DAB, 2.5 g 
nickel ammonium sulfate per 100 ml sodium acetate buffer with 0.3% H20 2 added in 10 µI 
increments). Tissue sections then were placed in sodium acetate buffer, transferred to cold 
PBS and left at 4°C overnight. Subsequently, the tissue was mounted on slides, dried, 
defatted and cover slipped. According to product specifications, the biotinylated anti-mouse 
lgG (Vector) has 25% cross-reactivity with rat lgG. We were able to reduce this non-
specific staining in the omit sections by diluting this secondary antibody. lmmunolabelled 
cells in the omit sections were subtracted accordingly to establish a baseline. 
3) Alz-50: Performed as above, except that 10% normal goat serum was used in 
the primary antibody diluent instead of normal horse serum. Alz-50 (courtesy of Dr. L. I. 
Binder) was used at a 1 : 1 000 dilution, and the secondary antibody was a peroxidase-
conjugated goat anti-mouse lgM (Boehringer Mannheim, Indianapolis, IN), diluted to 1 :200. 
4) GFAP: Performed the same way as tau-2 staining, except that 10% normal goat 
serum was used in the primary antibody diluent instead of normal horse serum. The GFAP 
antibody (Dako, Denmark) was used at a 1 :500 dilution. The secondary antibody was a 
goat anti-rabbit lgG (Vector) diluted 1: 1333. 
Experimental Design 
Group# 
2 
Experiment 1: Effects of AP 25-35 at 8 days postoperatively. 
n 
9 
9 
Drug (dose), right amygdala 
VEH ( 10.0 nmol TFA/3.0 µI H20) 
AP 25-35 (5.0 nmol/3.0 µI H20) 
Methods: Cresyl violet, tau-2, Alz-50 and GFAP staining. 
Both cresyl violet and tau-2 staining were performed on series from all the rats. 
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Because of limited amounts of the Alz-50 antibody, we were not able to stain all series. 
Alz-50 staining was performed on a series of sections from two AP 25-35 treated rats that 
showed intense tau-2 IR, and on the same number of VEH treated rats. GFAP staining was 
performed on a series from eight VEH treated rats and five AP 25-35 treated rats. 
Experiment 2: Effects of AP 25-35 at 32 days postoperatively. 
Group# n Drug (dose), right amygdala 
3 VEH (10.0 nmol TFA/3.0 µI H20) 
2 4 AP 25-35 (5.0 nmol/3.0 µI H20) 
Methods: Cresyl violet, tau-2, Alz-50 and GFAP staining. 
Cresyl violet, tau-2 and GFAP staining were performed on a series of sections from 
all the rats. Alz-50 staining was performed on a series from two of the VEH treated rats 
and all of the AP 25-35 treated rats. The Alz-50 and GFAP staining were performed 
simultaneously on sections from the rats sacrificed 8 days postoperatively. 
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In a separate experiment, we injected the same dose of the reverse peptide (A~ 35-
25) into the rat amygdala and examined GFAP and tau-2 IR at 8 days and 32 days 
postoperatively (n =2-3). The same VEH (n =2-3) was used for comparison. 
Data Analysis 
Tau-2 IR cells were counted from 12 coronal sections (40 µm) surrounding the 
cannula track. The number of tau-2 IR cells in distinct brain areas in the VEH and A~ 25-35 
treated animals were analyzed using at-test (SIGMASTAT, version 1.01; Jandel, San 
Rafael, CA). Reactive astrocytosis in the ipsilateral hippocampus was rated on a scale of 0-
2 +. An animal was considered positive if it exhibited ~ 1 + staining. The GFAP staining 
was analyzed using a one-tailed Fisher exact test (SIGMASTAT). The rating of the GFAP 
sections was based on the complexity of astrocytic branching within the hippocampus 
(0 =resting astrocytes, few processes; 1 + =reactive astrocytes, moderate branching; 
2 + =reactive astrocytes, extensive branching). 
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Results 
Experiment 1: Effects of AB 25-35 at 8 Days Postoperatively. 
Cresyl violet: 
No difference was seen in cresyl violet stained sections between VEH and AP 25-35 
treated rats except for proteinaceous deposits in the amygdala of AP 25-35 rats (Figure 3A-
B). These deposits were identical to the Congo red positive deposits that we have observed 
following AP 25-35 injections into the ventral pallidum/substantia innominata (VP/SI) (314). 
Proteinaceous deposits did not form at the site of injection in rats treated with the reverse 
peptide. Sections from the latter group of rats did not appear to differ from the VEH treated 
rats. 
Figure 3. Cresyl violet staining at 8 days postinjection. Coronal sections through VEH (A) 
and AP 25-35 (8) injection sites. The cannula track and the tip of the injection are seen in 
the VEH treated rat (A; arrowheads). Note the proteinaceous deposit (arrows) within the 
cavitation in B. No other histological differences were discerned between the VEH and AP 
25-35 groups. Scale bar=0.5 mm. 
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A~ 25-35 significantly increased tau-2 IR in the neuronal perikarya and processes 
ipsilaterally in the amygdala [A~ 25-35: (mean± SEM) 226 ± 95 IR cells; VEH: 10 ± 7, 
p<0.001], cingulate cortex [A~ 25-35: 94±30; VEH: 0, p<0.011 and hippocampus [A~ 
25-35: 251 ± 78; VEH: 5 ± 4, p < 0.001] (Figures 4-6). IR cells were also seen in other brain 
areas such as the parietal and pyriform cortices, hypothalamus, thalamus, globus pallidus, 
claustrum, substantia nigra, VP/St, and the entorhinal cortex. No contralateral staining was 
observed except in the hypothalamus and occasionally in the cingulate cortex. Sections 
from rats treated with the reverse peptide did not appear to differ from the VEH treated rats. 
A 
Figure 4. Tau-2 IR at 8 days postinjection. Coronal sections adjacent to VEH (A) and A~ 
25-35 (8, C) injection sites. C is a magnification of the area bracketed in 8. Virtually no 
tau-2 IR is observed in the VEH treated rat (A). A~ 25-35 induces neuronal cell body and 
processes tau-2 IR in the amygdala (8, C). Scale bar (A) =0.5 mm. Scale bar (C) =20 µm. 
51 
A 
Figure 5. Tau-2 IR at 8 days postinjection. Coronal sections adjacent to VEH (A) and AP 
25-35 (B, C) injection sites. C is a magnification of the area bracketed in B. Virtually no 
tau-2 IR is observed in the VEH treated rat (A). AP 25-35 induces neuronal cell body and 
processes tau-2 IR in the hippocampus (B, C), and cortical areas (8). Scale bar (A) =0.5 
mm. Scale bar (C) = 20 µm. 
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Alz-50: 
An increase in Alz-50 IR was observed in the amygdala of the A~ 25-35 treated 
animals. Several beaded fibers and an occasional neuronal perikarya were visualized with 
Alz-50 in the ipsilateral amygdala and to a lesser extent in the contralateral amygdala. 
Interestingly, no Alz-50 IR was observed in the basolateral amygdala. Moderate staining of 
similar morphology also was observed ipsilaterally in the VP/SI and there was faint staining 
ipsilaterally in the hippocampus. In addition, hypothalamic cell bodies and fibers were 
observed bilaterally in both VEH and A~ 25-35 treated rats. Hypothalamic IR in normal rats 
has been observed by others (32). 
Reactive astrocytosis was observed in the ipsilateral amygdala but there did not 
appear to be differences between A~ 25-35 and VEH treated animals. However, reactive 
astrocytosis was seen in the ipsilateral hippocampus of all the A~ 25-35 treated rats (5/5) 
but only in 50% of the VEH treated rats (4/8; p = 0.105). No reactive astrocytosis was 
observed in rats treated with the reverse peptide. 
Experiment 2: Effects of AB 25-35 at 32 Days Postoperatively. 
Cresyl violet: 
Microscopic analysis of the ipsi- and contralateral amygdala appeared to reveal 
neuronal shrinkage within the right amygdala (injected site) of A~ 25-35 treated rats when 
compared to the left amygdala. This finding, however, requires confirmation by quantitative 
analysis in a larger number of animals. Proteinaceous deposits were observed 32 days 
postinjection in the right amygdala bf A~ 25-35 treated rats. However, proteinaceous 
deposits did not form at the site of injection in rats treated with the reverse peptide. 
Sections from these rats did not differ from the VEH treated rats. 
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A~ 25-35 significantly increased tau-2 IR ipsilaterally in the amygdala (A~ 25-35: 
721 ±194 IR cells; VEH: 48±24, p<0.05) and hippocampus (A~ 25-35: 938±84; VEH: 
310 ± 161, p < 0.05) in rats 32 days postoperatively (Figure 6). As at 8 days 
postoperatively, IR cell bodies and processes were also seen in other brain areas such as the 
parietal and pyriform cortices, hypothalamus, thalamus, globus pallidus, claustrum, 
substantia nigra, VP/SI, and the entorhinal cortex. Contralateral staining was only observed 
in the hypothalamus and occasionally in the cingulate cortex. The staining appeared to be 
more intense than at 8 days postoperatively but a similar anatomical distribution was noted. 
Sections from rats treated with the reverse peptide did not appear to differ from the VEH 
treated rats. 
Alz-50: 
The pattern and morphology of Alz-50 staining was similar to that observed at 8 
days postoperatively but the intensity in the A~ 25-35 treated rats appeared to be greater at 
32 days postoperatively (Figure 7). 
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Figure 6. Quantitation of tau-2 IR cells at 8 days and 32 days postinjection. Following 
unilateral intra-amygdaloid injection, there was a significant increase in ipsilateral tau-2 IR 
cells in the amygdala, cingulate cortex and hippocampus in A~ 25-35 treated rats 8 days 
postoperatively (A), and in the amygdala and hippocampus 32 days postoperatively (B) 
when compared to VEH treated rats. Each bar represents the mean+ SEM of tau-2 IR cells 
from 12 sections (40 µm) surrounding the cannula track. (A) **p<0.01; ***p<0.001; (8) 
*p<0.05. 
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A B 
Figure 7. Alz-50 IR at 32 days postinjection. Coronal sections through VEH (A) and 
adjacent to AP 25-35 (8, C) injection sites. C is a magnification of the area bracketed in 8. 
Virtually no staining is observed in the VEH treated rat (A), but collection of red blood cells 
are seen at the tip of the injection site. Several beaded fibers and an occasional neuronal 
perikarya are visualized with Alz-50 in the amygdala of the AP 25-35 treated rat (8, C). 
Note the lack of staining in the basolateral amygdala. Scale bar (A) =0.5 mm. Scale bar 
(C) =20 µm. 
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At 32 days, no reactive astrocytosis was observed in the VEH treated animals. 
Reactive astrocytosis in the A~ 25-35 treated rats was predominantly observed within the 
right hemisphere. These histological changes were seen in areas such as the amygdala, 
hypothalamus and cortical regions but were seen most consistently within the hippocampus. 
Reactive astrocytosis was observed in the ipsilateral hippocampus (Figure 8) of all the A~ 
25-35 treated rats (4/4) but not in the VEH treated rats (0/3; p =0.029). No evidence of 
reactive astrocytosis was observed in rats treated with the reverse peptide. 
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Figure 8. GFAP IR 32 days postinjection. Coronal sections adjacent to VEH (A) and A~ 25-
35 (8, C) injection sites. C is a magnification of the area bracketed in B. Virtually no GFAP 
IR is observed in the VEH treated rat (A). In the A~ 25-35 treated rat a reactive astrocytosis 
is predominantly observed in the ipsilateral hippocampus (8, C; p =0.015). Scale bar 
(A) =0.5 mm. Scale bar (C) =20 µm. 
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Discussion 
We have demonstrated that a unilateral intra-amygdaloid injection of A~ 25-35 in the 
rat induces the appearance of abnormal tau proteins both within the ipsilateral amygdala as 
well as at distant sites as recognized by the tau-2 and Alz-50 antibodies. These cytoskeletal 
changes appeared to be progressive and associated with reactive astrocytosis. Studies have 
reported local effects immediately surrounding the injection site of A~ injections into rat 
cerebral cortex and hippocampus (91, 178, 180), but there are no reports on A~ injections 
into the rat amygdala, and their distal effects. 
The tau-2 antibody recognizes tau proteins in both the phosphorylated and non-
phosphorylated form. This antibody does not discriminate between normal tau and 
hyperphosphorylated Alzheimer's tau in unfixed tissue, but recognizes only the Alzheimer's 
tau in fixed tissue (259). The epitope that tau-2 recognizes has been localized to the alanine 
95 through alanine 108 sequence, in particular, amino acid 101 (346). On immunoblots, 
tau-2 has a higher affinity for bovine tau, that has serine in position 101, than human, 
mouse or rat tau, that all have praline in position 101. It has been suggested that the tau 
comprising paired helical filaments has a serine 101 peptide-like conformation similar to that 
seen for bovine tau (346). Therefore, the increase in tau-2 IR suggests that A~ 25-35 may 
be causing a conformational change in tau proteins. Tau-2 IR cells were seen consistently in 
several brain areas ipsilateral to the injection site of A~ 25-35 treated rats at 8 and 32 days 
postoperatively. The anatomical distribution of senile plaques and neurofibrillary tangles in 
AD suggests that A~ may act on nerve terminals to cause cytoskeletal alterations in axons, 
which ultimately lead to tangle formation within the perikarya (265). Therefore, the 
appearance of abnormal tau IR following intra-amygdaloid injections of A~ 25-35 can be 
expected in brain regions that project to the amygdala (Figure 9). Our results support this 
view. The hippocampus and cortical areas have prominent bidirectional connections with 
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the amygdala but the corpus striatum is one of only a few brain regions that receives 
amygdaloid fibers but does not project back to the amygdala (276). The observation of tau-
2 IR cells in the hippocampus and cortical areas and relative lack of reactive cells in the 
neostriatum supports the hypothesis that A~ 25-35 acts on nerve terminals to induce the 
appearance of abnormal tau proteins in brain regions that have efferent projections to the 
amygdala. It is unlikely that these distant effects are due to diffusion of the peptide from 
the site of injection into the ventricles, because A~ deposits were not observed outside the 
site of injection. In addition, induced tau IR and reactive astrocytosis were not observed in 
the ependymal lining of the ventricles. 
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Figure 9. Schematic diagram of the right hemisphere of a coronal section through the AP 
25-35 injection site. AP 25-35 in its p-pleated sheet conformation (stippled area in the 
amygdala) acts on nerve terminals to induce the appearance of abnormal tau proteins in 
brain regions that have efferent projections to the amygdala. The cingulate cortex and the 
hippocampus are examples of brain regions that have prominent efferent connections 
(dashed lines) with the amygdala. Amygdaloid interneurons are also shown projecting 
{dashed lines) towards the A~ 25-35 deposit. Tau-2 positive cell bodies are represented by 
black stars within white boxes. Abbreviations: CING: cingulate cortex; HIP: hippocampus; 
AMY: amygdala; Hb: habenula; f: fornix. 
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The Alz-50 antibody in immunocytochemical studies stains AD brain tissue (55) but 
its IR in normal brain tissue appears to depend on the method used (293). It demonstrates 
early changes in AD by recognizing abnormally phosphorylated tau protein (337). The 
location and nature of the epitope recognized by Alz-50 remains controversial. It has been 
reported to recognize an acid phosphatase sensitive phosphorylated epitope of tau that is 
localized within the 14-amino acid carboxy-terminal to the tubulin-binding domain of tau 
(337). However, the epitope also has been mapped to the amino-terminal region of tau 
proteins (105, 182). Although the epitope that Alz-50 recognizes may not be 
phosphorylated, the overall peptide conformation recognized by the antibody may be 
phosphorylation dependent. In the present study, the morphology and distribution of the 
Alz-50 staining differed from that of tau-2. Beaded fibers, but only an occasional perikarya, 
were visualized with Alz-50 whereas tau-2 IR was observed in cell bodies and processes. 
Alz-50 staining was predominantly observed in the ipsilateral amygdala, to a lesser extent in 
the contralateral amygdala, and ipsilaterally in the VP/SI and hippocampus. At present, 
there is no obvious explanation for the lack of IR in the basolateral amygdala. The ipsi- and 
contralateral amygdala are connected through the anterior commissure (276), which may 
explain the IR observed in the contralateral amygdala. In addition, the IR in the ipsilateral 
VP/SI and hippocampus can be explained by prominent anatomical connections between 
these brain regions and the amygdala (276). We did not attempt to quantify the effects of 
A~ 25-35 on Alz-50 IR because of the morphology of staining. lmmunohistochemistry was 
performed simultaneously on sections from rats sacrificed 8 and 32 days postoperatively. 
As with tau-2, staining appeared to be substantially more intense at 32 days postoperatively 
but the pattern was similar to that observed 8 days postoperatively. This supports the 
observation that A~ 25-35 induced effects on the cytoskeleton gradually increase up to 32 
days postoperatively. The A~ 25-35 induction in Alz-50 staining suggests that the peptide 
alters the conformation of tau proteins possibly through an increase in tau phosphorylation. 
We have recently found (unpublished observation) that A~ 25-35 increases Alz-50 IR on 
Western blots 8 days postoperatively. 
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There is no obvious explanation for the differences in distribution and morphology 
between Alz-50 and tau-2 staining. These two antibodies recognize different conformation 
dependent epitopes on tau proteins. A~ 25-35 may be inducing multiple conformational 
changes in tau proteins, which are differently stained using the two antibodies. The nature 
and extent of these conformational changes may be time dependent, brain region specific, 
and differ within the neuronal structure. 
It can be argued that the A~ 25-35 induction in tau-2 and Alz-50 IR does not arise 
from conformational change but rather is due to increased synthesis of tau proteins. We 
have performed Western blot analysis on the amygdala of rats sacrificed 8 days 
postinjection using the same experimental protocol as in this study. By using the tau-1 
antibody that reacts only with normal and unphosphorylated tau (16), no differences were 
observed in the molecular weights of tau-1 IR bands or their density when A~ 25-35 treated 
rats were compared to VEH treated rats (unpublished observation). This finding suggests 
that the A~ 25-35 induction in abnormal tau IR is not the result of an increased synthesis of 
tau proteins. 
The effects of A~ on tau IR may be mediated through an increase in intracellular 
calcium. A~ has been shown to increase intracellular calcium (7,218), and calcium influx in 
cultured rat hippocampal neurons caused by glutamate induces tau IR as recognized by the 
antibodies Alz-50 and 5E2 (216). Protein kinases are generally activated by increases in 
intracellular calcium and several of those have been shown to phosphorylate different sites 
on tau proteins (238). Therefore, A~ may increase the phosphorylation of tau proteins 
through an activation of kinases mediated by an increase in intracellular calcium. The 
activities of some phosphatases that may dephosphorylate tau proteins have been shown to 
be decreased in AD (111,311 ). Therefore, A~ 25-35 may also be decreasing the 
dephosphorylation of tau proteins through an inhibition of phosphatases. 
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The proteinaceous deposits observed at the site of injection, both at 8 and 32 days 
postinjection, were identical to those we have observed following injection of A~ 25-35 into 
the VP/SI (314). Those deposits were Congo red positive with birefringence under polarized 
light, suggesting that they were most likely composed of fibrillar A~ because the dye reacts 
with the peptide in its ~-pleated sheet conformation. Therefore, these findings further 
support the notion that A~ 25-35 is not readily degraded in vivo, and suggest that its toxic 
effects may gradually increase as long as the peptide is present in its toxic conformation (~­
pleated sheets). 
GFAP immunohistochemistry was performed in order to determine 1) if A~ 25-35 
increases reactive astrocytosis, like that seen surrounding senile plaques in AD; and, 2) if 
there is a correlation between the location and severity of abnormal tau and GFAP IR. 
Following stab wounds of the rodent cerebrum reactive gliosis reaches maximum intensity 
3-7 days postoperatively (253). The contra lateral hemisphere is rarely affected and the glial 
reaction is transient in nature and declines to nearly normal appearance by 3 weeks. 
Therefore, the non-specific damage caused by the cannula placement may explain the similar 
amygdaloid GFAP IR in A~ 25-35 and VEH treated rats at 8 days postoperatively. This 
injury related effect may also explain the reactive gliosis in the ipsilateral hippocampus of 
some of the VEH treated rats and thereby the lack of a significant effect of A~ 25-35 at 8 
days postoperatively (p = 0.105). Microscopic analysis of cresyl violet stained sections did 
not reveal any hippocampal neuronal loss. However, numerous tau-2 IR cells were observed 
in the ipsilateral hippocampus at this timepoint, suggesting an association between neuronal 
cytoskeletal changes and reactive astrocytosis. The transient nature of the glial reaction 
caused by the cannula placement is supported by the lack of reactive astrocytosis in the 
VEH treated rats 32 days postoperatively. Reactive astrocytosis was consistently observed 
in the ipsilateral hippocampus of the A~ 25-35 treated rats at this timepoint (p = 0.029). 
These observations suggest a long lasting effect of A~ 25-35 on astrocytic reactivity in a 
brain region that has prominent efferent connections with the amygdala. 
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In a separate experiment, we injected the same dose of the reverse peptide (A~ 35-
25) into the rat amygdala and performed cresyl violet, tau-2 and GFAP staining at 8 and 32 
days postoperatively. No difference was seen between rats treated with VEH and the 
reverse peptide. It did not form proteinaceous deposits at the site of injection and did not 
induce significant tau-2 IR or reactive astrocytosis. Therefore, the histopathological effects 
of A~ 25-35 are specifically caused by that particular amino acid sequence. The effects of 
A~ 25-35 in present study, furthermore, are not caused by its greater acidity (pH 3.5-3.9) 
than the VEH solution (pH 5.9-6.0), as the acidity (pH 3.6) of the same dose of the reverse 
peptide, was similar to that of A~ 25-35. 
Animal models can be evaluated in terms of construct validity, face validity and 
predictive validity. We believe that this model has construct validity because we are 
injecting a fragment of a peptide, that may play a prominent role in the etiology of AD, into 
a brain region that is affected early in the disease. The most appropriate face validity of an 
animal model of AD would be the demonstration of senile plaques associated with reactive 
astrocytes, neurofibrillary tangles, and neuronal cell loss in the same brain regions as 
observed in AD. It is unlikely, however, that this effect can be obtained using a single 
injection of A~ into rat brain, but this approach may demonstrate the early histopathological 
changes in AD. In our opinion, the present rat model has a relatively high face validity 
because of the induction of abnormal tau proteins and reactive astrocytes in brain regions 
where the primary and early histopathological changes in AD are observed. Currently, no 
definitive transgenic animal models are available that resemble all aspects of AD, although 
plaque-like A~ deposits have been observed (98). The predictive validity of the present rat 
model, as well as future transgenic models, will ultimately determine their usefulness in 
screening potential drugs for therapy. 
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In conclusion, these data suggest that injection of Af3 25-35 into the right amygdala 
of young rats induces progressive transsynaptic cytoskeletal and astrogliotic reactions that 
gradually spread from the amygdala to brain regions that have prominent efferent 
connections with that area. These findings also suggest a direct association between 
plaque and tangle formation in AD, and support the use of this rat model to screen drugs 
that may attenuate or enhance the initial pathological events associated with AD. 
CHAPTER IV 
LATERALITY IN THE HISTOLOGICAL EFFECTS OF INJECTIONS OF AMYLOID-~ 25-35 INTO 
THE AMYGDALA OF YOUNG MALE FISCHER RATS 
Abstract 
We have observed that single amyloid-~ 25-35 (A~) injections (5.0 nmol) into the 
right amygdala of rats produce progressive cytoskeletal and astrogliotic reactions not only 
within the amygdala, but also in distal brain regions that project to the amygdala. To 
determine if these effects are potentiated by bilateral injections, we injected A~ (5.0 nmol) 
into the left and right amygdala of young male Fischer rats. Animals were sacrificed at 32 
days postoperatively. Bilateral infusions of A~ induced significant neuronal shrinkage, tau-2 
neuronal staining and reactive astrocytosis within the right amygdala and/or hippocampus, 
compared to vehicle treated rats. Surprisingly, the same brain regions within the left 
hemisphere were significantly less affected even though no differences were observed 
between the left and right amygdala in the size of Congo red positive A~ deposits. 
Unilateral injections of A~ into the left amygdala led to significant histological changes in the 
right amygdala and hippocampus but not in the same brain regions within the left 
hemisphere. These results suggest a laterality in the histopathological effects of A~ in male 
Fischer rats. Identification of the cause for the lateralized effect of A~ may prove valuable 
for understanding the etiology of Alzheimer's disease and provide possible therapeutic 
strategies designed to slow the progression of the disease. 
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Introduction 
The histopathological characteristics of Alzheimer's disease (AD) include senile 
plaques, reactive astrocytes, neurofibrillary tangles, and neuronal cell loss in several brain 
regions. Senile plaques consist predominantly of amyloid-~ (A~) 1-42 ( 103,214,233,285), 
which is derived from a large membrane spanning protein, the amyloid-~ precursor protein 
(APP) ( 1 66). Mutations in APP in some forms of familial AD are associated with an elevated 
production of A~ (33,39,331 ). APP is overexpressed in Down's syndrome (248,291 ), and 
individuals with this disease invariably develop the neuropathological hallmarks of AD 
(23, 1 87). The proposed role for A~ in the pathogenesis of AD is further supported by the 
neurotoxicity of A~ (369,370), that includes amino acids 25-35 of the peptide (370). A~ 
toxicity depends on its aggregation state (269,273), and requires the assembly of A~ into 
amyloid fibrils composed of a ~-pleated sheet structure (203). Other amyloidogenic peptides 
also are toxic to neurons in vitro, including amylin, serum amyloid P component, and a 
peptide derived from the prion protein (87,202,222,338). These findings suggest that the 
structure of the fibril, rather than its amino acid sequence, is responsible for its toxicity. 
The discovery of the association of AD with inherited APP mutations led to the development 
of transgenic mouse models containing these mutations. Recently, two mouse models have 
been described that contain age dependent congophilic A~ plaques similar to those observed 
in AD (98, 145), and in one of these models these changes are associated with behavioral 
impairments (145). 
The main component of neurofibrillary tangles is paired helical filaments ( 168,335), 
which consist largely of the microtubule associated protein tau in an abnormal state of 
phosphorylation ( 171, 182,355,356). Only recently have a few studies demonstrated a 
direct association between plaque and tangle formation using in vitro and in vivo models. In 
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vitro studies have demonstrated that AP increases tau protein kinase I (TPK I) activity (332), 
induces tau immunoreactivity (IR) (26,207), and that the neuronal death caused by AP can 
be prevented with TPK I antisense oligonucleotides (332). In vivo studies have reported 
that AP can induce tau IR in the vicinity of the injection site (91, 178, 180,317), as well as at 
distal sites (317). Also, one report indicates that injection of hyperphosphorylated tau into 
rat brain induces AP IR (312). 
In the AD brain, reactive astrocytes are found in high abundance surrounding senile 
plaques (70). Glial fibrillary acidic protein (GFAP) (77) is a component of the glial 
intermediate filaments that form part of the cytoskeleton, and is found predominantly in 
astrocytes. GFAP levels in AD brains are increased 8 to 16 fold compared to control brains 
(21,60). Recent in vitro (34,141,271) and in vivo (317) findings suggest that AP induces 
reactive astrocytosis. 
The major pathological changes in AD are found in regions of the medial temporal 
lobe, including the amygdala (265). Previously, we observed that single AP 25-35 injections 
(5.0 nmol) into the right amygdala of rats produce progressive (8 vs. 32 days) cytoskeletal 
and astrogliotic reactions not only within the amygdala, but also in distal brain regions that 
project to the amygdala (317). To determine if these effects are potentiated by bilateral 
injections of Ap, we injected AP 25-35 (5.0 nmol) into the left and right amygdala of young 
male Fischer-344 rats. The present study suggests that there is a laterality in the 
histological effects of AP. 
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Materials and Methods 
Animals 
Male Fischer-344 rats were obtained from the NIA colony at Harlan Sprague-Dawley 
(Indianapolis, IN). At the time of arrival, the rats weighed 250-300 g and were 3-4 months 
of age. The animals were housed individually, maintained on a 12 h light-dark cycle (lights 
on at 07:00 h) in a AAALAC approved facilities, had access to food and water ad libitum, 
and were habituated to their new environment for 2-3 weeks prior to surgery. 
A~ 25-35 (BACHEM, Torrance, CA) was supplied as a trifluoroacetic acid (TFA) salt. 
At the time of surgery, information was not available from the supplier regarding the amount 
of TFA per mg of the salt of the peptide. According to the supplier, there is not a direct 
stoichiometric relationship between the content of A~ 25-35 and TFA, in other words it is 
not known how many mol of TFA there are in each mol of the TFA salt of A~ 25-35. The 
peptide content was 77% ( ± 3%) with the remaining 23% consisting of TFA and H20, and 
the purity of the peptide was > 98%. We assumed that there are 2 nmol of TFA per 1 nmol 
of A~ 25-35, that is TFA content of 16.7% per mg of the salt. Recent information from the 
supplier indicates that the TFA content is 9. 7 % . The peptide and its respective vehicle 
(VEH; TFA, sodium salt; Sigma) were dissolved in Nanopure® water (H20) immediately 
before use and stored at 4 ° C between injections. 
Surgery 
Surgery was performed as described previously (317). Briefly, the animals received 
bilateral injections of 5.0 nmol/3.0 µI (n = 20), or its respective VEH (n = 13), into the 
amygdala. The rats were either injected first into the right amygdala and subsequently into 
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the left amygdala (A~ rats= 1 O; VEH rats= 7), or injected simultaneously into the right and 
left amygdala (A~ rats= 10; VEH rats= 6). In addition, a few rats (A~ rats= 4; VEH rats= 2) 
received unilateral injections of A~ 25-35 (5.0 nmol/3.0 µI) into the left amygdala. A Kopf 
stereotaxic instrument was used with the incisor bar set at 3.3 mm below the interaural line. 
Injection coordinates measured from the bregma and the surface of the skull (AP - 3.0, ML 
± 4.6, DV - 8.8) were empirically determined based on the atlas of Paxinos and Watson 
(261 ). 
Animal Sacrifice, Tissue Preparation and Histology 
The animals were anesthetized with sodium pentobarbital ( 100 mg/kg, 
intraperitoneally) and perfused transaortically 32 days postoperatively, as previously 
described (317). Serial coronal sections (40 µm) were cut with five series of sections at 0.2 
mm intervals saved for histological analysis of 1) cresyl violet, 2) tau-2, 3) GFAP, and 4) 
Congo red staining. lmmunohistochemistry was performed as previously described (317). 
Briefly, sections (40 µm) were incubated in tau-2 (Sigma, St. Louis, MO) primary antibody at 
a 1 :500 dilution for 24 h at room temperature. An anti-mouse immunoglobulin (lg) G 
secondary antibody (Vectastain ABC Elite kit, Vector Laboratories, Burlingame, CA) was 
used at a 1 :2000 dilution. GFAP staining was performed the same way as the tau-2 
staining. The GFAP antibody (Dako, Denmark) was used at a 1 :500 dilution. The 
secondary antibody was a goat anti-rabbit lgG (Vector) diluted 1: 1333. Omit sections for 
tau-2 and GFAP were obtained by omitting the primary antibody. According to product 
specifications, the biotinylated anti-mouse lgG (Vector) has 25% cross-reactivity with rat 
lgG. We were able to reduce the intensity of this non-specific staining by diluting the 
secondary antibody. The staining intensity was always substantially less in the omit 
sections than in sections treated with the primary tau-2 antibody. lmmunolabelled neurons 
in the omit sections from the same animal were subtracted accordingly to establish a 
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baseline. In the VEH treated animals, the number of cells in the omit sections, regardless of 
the intensity of staining, was 43% of the total cell number in the primary antibody sections. 
In the A~ treated rats, the number of cells in the omit sections was 23% of the total cell 
number in the primary antibody sections. This percentage (23%) is in accordance with the 
25% cross-reactivity of the secondary antibody. There was relatively more non-specific 
staining in the VEH treated rats (i.e. 43% of total staining) than might be expected but this 
may be due to the fact that few VEH treated animals had tau-2 positive cells (31 %), and 
there was a low number of positive cells in those animals. 
Data Analysis 
The A~ deposits, neuronal shrinkage and tau-2 staining were analyzed quantitatively. 
The size of the deposits and the neuronal perikarya were measured, and tau-2 IR neurons 
were counted. Reactive astrocytosis was analyzed semi-quantitatively by using a rating 
scale. 
An image analysis system (NIH Image 1.49) was used to determine the size of the 
A~ deposits and neuronal shrinkage within the left and right amygdala. The area of the A~ 
deposits was measured at 0.2 mm intervals. These data were analyzed using at-test 
(SIGMASTAT, version 1.01; Jandel, San Rafael, CA) for comparison of the deposit area in 
the left vs. right amygdala. The basolateral nucleus within the amygdala can be divided into 
parvicellular and magnocellular subnuclei based on the cytoarchitecture of the neurons. The 
cells within these subnuclei have a relatively uniform appearance and their boundaries are 
easily identified. The magnocellular division is located mainly rostral and medial to the 
parvicellular division. The area of 10 of the largest magnocellular cells (X400 magnification) 
within the left and right basolateral amygdala was measured in one cresyl violet stained 
section per animal slightly rostral to the injection site, and we carefully chose sections at a 
similar coronal level. The average area of these 10 cells was calculated and the data were 
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analyzed by a t-test for the unilateral A~ injections, and a two-way analysis of variance 
(ANOVA; SIGMASTAT) for the bilateral injections, followed by a Newman-Keuls' multiple 
range test for post hoc comparisons. Tau-2 IR neurons were counted in the left and right 
amygdala in six sections surrounding the injection site, and in six hippocampal sections 
including and caudal to the injection site. Tau-2 IR neurons were also counted in omit 
sections and subtracted accordingly. These data were analyzed using a two-way ANOVA 
for the amygdala and hippocampus separately, followed by a Newman-Keuls' multiple range 
test for post hoc comparisons. When the tau-2 data failed a normality test, it was analyzed 
by a two-way ANOV A on ranks. The correlation between the number of tau-2 positive 
neurons and neuronal cell size within the left and right amygdala, as well as the correlation 
between the number of tau-2 positive neurons within the amygdala and hippocampus, was 
analyzed using the Pearson product-moment correlation (SIGMASTAT). Reactive 
astrocytosis in the left and right hippocampus was rated on a scale of 0-2 + . An animal 
was considered positive if it exhibited ~ 1 + staining. These data were analyzed using a 
Fisher exact test, one-tail (SIGMASTAT). The rating of the GFAP sections was based on the 
complexity of astrocytic branching within the hippocampus (0 =resting astrocytes, few 
processes; 1 + = reactive astrocytes, moderate branching; 2 + = reactive astrocytes, 
extensive branching). The observers did not know which rat numbers corresponded to 
which treatment. However, the A~ treated animals were easily identifiable because of the 
proteinaceous deposits within the amygdala. 
No statistical difference was discerned, in any of the parameters analyzed, between 
rats injected first into the right amygdala and subsequently into the left amygdala, and 
animals injected simultaneously into the left and right amygdala, so they were combined in 
the subsequent analyses. 
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Results 
Bilateral Injections into the Amygdala 
AB Deposits 
Proteinaceous deposits were observed bilaterally in the amygdala of the AP 25-35 
treated rats (Figures 1 OA, B; 11; 14A). The location of the deposits did not vary between 
the left and right amygdala. The deposits were found consistently medial to the basolateral 
nucleus at the injection site, and their size appeared to be less than that of the basolateral 
nucleus. These deposits were Congo red positive (apple-green birefringence under polarized 
light; Figure 11 ), similar to those we observed following AP 25-35 injections into the ventral 
pallidum/substantia innominata (VP/SI) (314). Of the 20 rats injected bilaterally with AP 25-
35, deposits were observed bilaterally in 18 rats, and unilaterally in 2 rats. Analysis of the 
area of these deposits within the left vs. the right amygdala revealed no significant 
differences (Figure 14A). 
Cresyl Violet 
Analysis of the areas of 1 0 of the largest magnocellular cells within the left and right 
basolateral amygdala revealed a treatment effect of AP 25-35 [F( 1, 62) = 18.649, 
p<0.001]. Laterality was also observed [F(1,62)=31.981, p<0.001], and there was a 
significant treatment x laterality interaction [F(1,62) = 9.469, p = 0.003]. Post hoc analysis 
revealed that bilateral intra-amygdaloid injections of AP 25-35 caused neuronal shrinkage 
within the right amygdala [cell area= 1433 ± 82 µm 2 (SEM); p < 0.01], compared to VEH 
injections [cell area= 2040 ± 84µm 2 ; Figure 148]. The left amygdala in the AP treated rats 
[cell area=2150±71µm 2] was significantly less affected than the right amygdala (p<0.01; 
Figure 148). There was no significant difference between the cell area of the left [cell 
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area= 2252 ± 80µm 2] and the right [cell area= 2040 ± 84µm 2] amygdala in the VEH treated 
rats. All nuclei within the right amygdala appeared to be equally affected but the shrinkage 
was most obvious in the large neurons within the basolateral amygdala (Figure 1 OA, 8). 
The neuronal atrophy appeared to extend into other brain regions within the right 
hemisphere, such as cortical areas. Cell bodies within the hippocampus overlapped and, 
therefore, analysis of cell shrinkage was not performed in that brain region. 
Figure 10. Neuronal shrinkage within the right amygdala. Cresyl violet stained coronal 
section (X63) through the left (A) and right (8) amygdala in a bilaterally injected A~ rat. A~ 
deposits are seen bilaterally adjacent to the basolateral nuclei. Note the neuronal shrinkage 
within the right (8) but not the left basolateral nucleus (A). In this animal, the average area 
of 1 0 of the largest magnocellular cells was 1 986 ± 1 87 µm 2 (SD) in the left nucleus, and 
1016 ± 178 µm 2 in the right nucleus. 
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Figure 11. Congo red positive AJ3 deposit. Congo red stained coronal section (X63) 
through the injection site within the left amygdala in a bilaterally injected AJ3 rat. Note the 
birefringence of the AJ3 deposit under polarized light that indicates a (3-pleated sheet 
structure. 
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There was a treatment effect of A~ 25-35 in the induction of specific neuronal tau-2 
staining within the amygdala [F(1,60)=22.150, p<0.001) and the hippocampus 
[F(1,60)=34.513, p<0.001) (Figure 14C, D). Laterality was observed in the amygdala 
[F(1,60) = 31. 782, p < 0.0011 and the hippocampus [F(1,60) = 9.266, p =0.003] (Figure 12; 
14C, D). There was also a significant treatment x laterality interaction within the amygdala 
[F(1,60) = 8.198, p =0.006], but not within the hippocampus [F(1,60) = 3.096, p =0.084). 
Post hoc analysis for the treatment effect revealed a significant increase in the number of 
tau-2 IR neurons in the A~ treated rats within the right amygdala (p<0.01) and the right 
hippocampus (p < 0.01 ), compared to the same brain regions in the VEH treated rats. 
Interestingly, there was also a significant increase in the number of tau-2 positive neurons 
within the left hippocampus in the A~ treated rats (p < 0.05), compared to VEH treated rats. 
Post hoc analysis for the laterality effect revealed a significant increase in the number of tau-
2 IR neurons in the right amygdala (p < 0. 01 ) and the right hippocampus (p < 0. 01 ), 
compared to the same brain regions within the left hemisphere in the A~ treated rats. There 
also appeared to be an increase in tau-2 IR neurons in other brain areas, predominantly on 
the right side, including the cingulate, parietal and pyriform cortices, hypothalamus, 
thalamus, globus pallidus, claustrum, substantia nigra, VP/SI, and the entorhinal cortex (data 
not shown). Within individual animals, there was a significant positive correlation between 
the number of tau-2 IR neurons within the amygdala and hippocampus (r=0.833, 
p<0.001 ). There was also a significant negative correlation between the number of tau-2 
positive cells and cell size within the left and right amygdala (r=-0.67, p<0.001 ). 
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Figure 12. Laterality in tau-2 IR. Tau-2 stained coronal section through the left (A) and 
right (C) hippocampus (X63), and the left (8) and right (D) amygdala (X63) in a bilaterally 
injected Aj3 rat. E (X250) is a magnification of the area bracketed in C. No tau-2 IR is 
observed within the left hippocampus (A) or the left amygdala (8) although an Aj3 deposit is 
visible (arrows). Note the neuronal tau-2 IR within the right hippocampus (C, E) and the 
right amygdala (D) in this same animal. 
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Reactive astrocytosis was observed predominantly within the right hippocampus in 
AP treated rats (p<0.001), compared to VEH treated rats (Figures 13C-F; 14E). The left 
hippocampus was significantly less affected (p < 0.001; Figure 14E). These histological 
changes were seen most consistently within the right hippocampus although other areas of 
the right hemisphere appeared to be also affected. However, it should be noted that the left 
hippocampus had occasionally moderate reactive astrocytosis (Figure 1 3A, 8) in rats with 
the most severe gliosis in the right hippocampus (Figure 13C, D). Reactive astrocytes 
appeared to be also associated with the AP deposits, and with the cannula track in both 
treatment groups. 
Figure 13. Laterality in GFAP staining. GFAP stained coronal section through the left (A, 8) 
and right (C, D) hippocampus in a bilaterally injected AP rat, and through the right (E, F) 
hippocampus in a bilaterally treated VEH rat. Reactive astrocytosis is moderate in the left 
hippocampus (A, 8), whereas prominent reactive astrocytosis is observed in the right 
hippocampus (C, D). No effect is observed in the VEH treated rat (E, F). 8, D and F (X250) 
are magnifications of the areas bracketed in A, C and E (X63), respectively. The AP infused 
rat represents a rating of 1 + in the left hippocampus and a rating of 2 + in the right 
hippocampus. The VEH injected rat represents a rating of 0 in the right hippocampus. 
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Figure 14. A~ deposits, neuronal shrinkage, tau-2 and GFAP staining. A quantitative 
analysis of the size of the AP deposits (A) and neuronal shrinkage (B) within the right 
amygdala vs. the left amygdala. Each bar represents the mean+ SEM of n = 13-20 rats. No 
significant difference was seen between the left and right amygdala in the size of the AP 
deposits. A quantitative analysis of neuronal tau-2 IR within the left and right amygdala and 
hippocampus is shown in C and D, respectively. Each bar represents the mean+ SEM of 
n = 13-19 rats. A semi-quantitative analysis of reactive astrocytosis within the left and right 
hippocampus is illustrated in E. The data are presented as the percentage of positive rats 
(rating of 21 +) of total rats (n = 13-20) analyzed. 
*** p<0.001 [Ap RHIP vs. VEH RHIP]; ### p<0.001 [Ap RHIP vs. AP LHIP]; ** p<0.01 
[Ap RAMY or RHIP vs. VEH RAMY or RHIPl; ## p<0.01 [Ap RAMY or RHIP vs. AP LAMY 
or LHIP]; x p < 0.05 [Ap LHIP vs. VEH LHIP]. Abbreviations: LHIP: left hippocampus; RHIP: 
right hippocampus; LAMY: left amygdala; RAMY: right amygdala; LDEP: AP deposits, left 
amygdala; RDEP: AP deposits, right amygdala. 
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Unilateral Injections into the Left Amygdala 
Analysis of the areas of 1 0 of the largest magnocellular cells within the left and right 
basolateral amygdala in the AP treated rats revealed a significant difference [t = 3.4 72, 
df = 6, p = 0.013] between the left [cell area= 2309 ± 92 µm 2(SEM)l and right amygdala [cell 
area= 1535±203 µm 2]. There was a treatment effect of AP 25-35 in the induction of 
specific neuronal tau-2 staining within the amygdala [F(1,8) = 6.122, p = 0.038], but not 
within the hippocampus. Laterality in tau-2 neuronal staining was also observed in the 
amygdala [F(1,8) = 55.102, p < 0.001 l (Figure 15A, 8), but not in the hippocampus. Post 
hoc analysis revealed a significant increase in the number of tau-2 IR neurons within the 
right amygdala in the AP treated rats (267 ± 95) compared to the right amygdala in the VEH 
treated rats (78± 10, p<0.05). There was also a significant increase in the number of tau-2 
IR neurons in the right amygdala vs. the left amygdala in the AP (right= 267 ± 95; 
left= 1 ± 1, p < 0.01) and the VEH treated rats (right= 78 ± 10; left= 0, p < 0.05), 
respectively. In all 4 rats injected with AP 25-35 into the left amygdala, reactive 
astrocytosis was observed in the right hippocampus but not the left hippocampus 
(p = 0.014). The regional distribution of these histological changes appeared similar to that 
observed following unilateral injections into the right amygdala (317), as well as following 
bilateral infusions. 
Figure 15. Tau-2 IR within the right amygdala following injection of AP 25-35 into the left 
amygdala. Tau-2 stained coronal section (X63) through the left (A) and right (8) amygdala 
in an AP treated rat injected only into the left amygdala. No tau-2 IR is observed in the left 
amygdala (A), although an AP deposit is visible. Note the induction of neuronal tau-2 IR 
within the right amygdala (8) in this same animal. · 
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Discussion 
We have confirmed our previous finding (317) that injection of A~ 25-35 into the 
right amygdala induces neuronal cytoskeletal changes and reactive astrocytosis within the 
amygdala, as well as at distal sites within the right hemisphere. Surprisingly, following 
bilateral injections, these changes were predominantly observed within the right amygdala 
and hippocampus whereas the same brain regions in the left hemisphere were significantly 
less affected. To our knowledge, this is the first report demonstrating a laterality in the 
histological effects of A~ injected intracerebrally. 
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The reproducibility of A~ toxicity in vivo has been inconsistent 
(42,91,99,101,102,178,180,314,317,320,354). This may be due to variations in: 1) the 
conformational state (25,269,273), dose, and sequence of A~; 2) method of administration; 
3) pathological endpoints measured; 4) what brain region and/or hemisphere is injected 
(present study); 5) postoperative interval; and, 6) species and/or strain used. 
The anatomical distribution of senile plaques and neurofibrillary tangles in AD 
suggests that A~ may act on nerve terminals to cause cytoskeletal alterations in axons, 
which ultimately lead to tangle formation within the perikarya (265). This notion is 
supported by the observation that the APP is predominantly located in the synaptic zone of 
neurons (301 ). Therefore, deposition of A~ fibrils and their initial toxic effects would 
primarily occur near their site of generation, namely at the nerve terminals. These effects 
then would gradually spread to distal brain regions that send axons to the area of initial 
deposition. Our findings support this view. 
As discussed previously (317), the increase in tau-2 IR suggests that A~ 25-35 is 
causing a conformational change in tau proteins. These cytoskeletal changes are associated 
with neuronal shrinkage and reactive astrocytosis, and this may simulate the initial 
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histopathological changes that occur in AD. Reactive astrocytosis appears to be a more 
sensitive marker of toxicity than tau-2 IR and neuronal shrinkage, but the AP 25-35 effects 
are comparable using these three different markers (Figure 14). There appeared to be a 
good correlation within individual rats between the extent and regional distribution of 
reactive astrocytosis, cytoskeletal changes, and neuronal shrinkage. 
Congo red positive (apple-green birefringence under polarized light) AP deposits were 
consistently observed at the site of injection. This indicates that the deposits were 
composed of a p-pleated sheet structure, the prominent conformation of AP in senile 
plaques. It can be argued that although the aggregation state of the peptide can be revealed 
by Congo red, AP immunostaining is necessary to prove the identity of the peptide. 
Unfortunately, there is no antibody commercially available that specifically detects AP 25-
35. However, the characteristic apple-green birefringence was not observed in VEH treated 
rats but always in AP treated rats with proteinaceous deposits. The consistency and 
persistence of AP deposits within the brain likely depends on several factors, such as the 
method of administration, solvent, dose, volume, sequence of Ap, and brain region injected. 
The presence of heparan sulfate proteoglycans has been shown to be important for 
consistent in vivo deposition of AP 1-40, and persistence of fibrillar AP in the rat 
hippocampus (321). Furthermore, AP 25-35 deposits within the rat nucleus basal is are 
degraded more rapidly than AP 1-40 deposits ( 102). AP in vitro develops protease 
resistance to degradation when polymerized into fibrils (252), and acetylcholinesterase 
(AChE) has been shown to promote the formation of and/or stabilize AP fibrils (150). Since 
the basolateral amygdala, adjacent to the injection site, contains very high levels of AChE 
(261 ), this proposed role of AChE may explain the consistency and persistence of the AP 
fibrils in the present study. Importantly, no hemispheric differences were observed in the 
size of the AP deposits (Figure 14A), indicating that the laterality in the histological effects 
of AP 25-35 can not be explained by variations in fibril formation and/or degradation 
between the left and right amygdala. 
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Previously, we have injected the same dose of the reverse peptide (AP 35-25) into 
the right amygdala and performed cresyl violet, tau-2 and GFAP staining at 8 and 32 days 
postoperatively (317). No difference was seen between rats treated with VEH and the 
reverse peptide. AP 35-25 did not form proteinaceous deposits at the site of injection and 
did not induce significant tau-2 IR or reactive astrocytosis. Therefore, the histopathological 
effects of AP 25-35 are specifically caused by that particular amino acid sequence. 
We tried to exclude experimental artifacts by measuring three different cellular 
variables. Staining with antibodies for abnormal conformation of tau, for GFAP, and cresyl 
violet staining all suggested a laterality in the effects of AP 25-35. Also, because both the 
left and right amygdala were treated in exactly the same manner, each side served as an 
internal control for the other side. In addition, unilateral injections into the left amygdala 
alone caused histopathology only within the right amygdala and hippocampus. This 
observation indicates that surgical damage to the right hemisphere is not the principal 
source for the histopathological changes. The observed laterality effect, therefore, is unlikely 
to be due to an experimental artifact. We are currently investigating injections into other 
areas of brain, as well as different strains of rats to determine if the laterality effect of AP 
25-35 is brain region and/or strain specific. 
At present, there is no obvious explanation for the laterality effects of AP 25-35. In 
four rats, unilateral injections into the left amygdala caused an induction in tau-2 IR within 
the right amygdala but not the left amygdala (p<0.01; Figure 15A, 8). Also, reactive 
astrocytosis was observed within the right hippocampus in all 4 rats but not the left 
hippocampus (p=0.014). The regional distribution of these histological changes within the 
right hemisphere appeared to be similar to that observed following bilateral infusions, as well 
as following unilateral injections into the right amygdala (317). Since the left and right 
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amygdala are connected through the anterior commissure (276), A~ 25-35 may be affecting 
the efferent terminals of neurons whose cell bodies originate within the right amygdala, and 
the laterality may be explained by hemispheric differences in secondary responses such as 
immune functions (249). 
Some investigators have demonstrated lateralization in the involvement of the rat 
amygdala in learning and memory (15,45-47), and lesions of various brain regions in rats 
(36,61, 121, 184,262,281,329,342) and mice (10) have asymmetrical effects. Ligation of 
the right middle cerebral artery has been shown to lead to hyperactivity and reductions in 
norepinephrine and dopamine, whereas ligation of the left middle cerebral artery has no 
behavioral or neurochemical effects (281). Also, occlusion of the left or right middle 
cerebral artery has different effects on mean arterial pressure, renal sympathetic nerve 
discharge, and plasma norepinephrine levels ( 1 21). Suction lesions of the right frontal 
cerebral cortex induce hyperactivity (61,262), that is accompanied by a bilateral decrease in 
norepinephrine concentrations (262). However, identical lesions of the left cortex do not 
produce hyperactivity (61,262) or a decrease in norepinephrine concentrations (262). Left 
cortical ablations affect mainly the activity of serotonergic inputs to the right neocortex, 
whereas ablations of the right cortex influence the activity of the catecholaminergic inputs 
to the left cortex ( 1 0). Ablations of the prefrontal or parietal cortices lead to lateralized 
brain immunomodulation (342). Kainic acid injections into the right frontal cortex produce a 
significantly greater hyperactivity than identical injections into the left hemisphere ( 1 84). 
Striatal lesions with 6-hydroxydopamine lead to greater dopamine depletion in right-lesioned 
rats than in left-lesioned rats (329). Also, left and right 6-hydroxydopamine lesions of the 
medial prefrontal cortex differentially alter subcortical dopamine utilization and the behavioral 
response to stress (36). 
Asymmetries have been observed in the histopathological hallmarks (52,235), and in 
the reductions in choline acetyltransferase activity (235,287) in individual cases of AD, but 
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preferential involvement of either hemisphere has not been demonstrated in groups of AD 
patients. Interestingly, asymmetry in the density of senile plaques diminishes with 
increasing neuropathological severity (235), suggesting that laterality may be more 
prominent in the initial stages of the disease. In AD, there is an extensive neuronal loss and 
shrinkage in all subdivisions of the amygdala (340), but no left-right hemispheric differences 
were detected in total neuron numbers in a study of 9 AD cases (340). However, 
hemispheric laterality in cerebral metabolism and perfusion in AD has been demonstrated in 
several studies. In most of these reports, there is no left-right preference in this asymmetry 
(37,68,95, 113, 129-132,254). On the other hand, some findings indicate a preferential 
involvement of the left (197,306) or the right hemisphere (239). In addition, early onset 
cases of AD have been associated with a greater prevalence of a left (247,306) or right 
( 148) hemispheric dysfunction compared to late onset AD cases. Other studies have found 
no correlation between a hemispheric dysfunction and the severity of the illness, suggesting 
that if there is a laterality in AD it reflects subtypes of the disease more than a generalized 
phenomena (197,239). 
Overall, we have demonstrated reproducible histopathological effects of intra-
amygdaloid injections of AP 25-35 that in young inbred male Fischer-344 rats are found 
primarily within the right amygdala and hippocampus. The same brain regions within the 
left hemisphere are significantly less affected. These findings support the use of this rat 
model as a reliable tool to screen drugs that may alter the initial pathological events 
associated with deposition of AP fibrils containing the same p-sheet structure that is 
observed in senile plaques in AD. It may serve as a relatively inexpensive and efficient tool 
to screen drugs that may interfere with the fibrillogenesis of Ap, enhance its degradation, 
and/or attenuate its toxicity. Furthermore, identification of the cause for the lateralized 
effect of AP 25-35 may prove valuable for understanding the etiology of AD and provide 
possible therapeutic strategies designed to slow the progression of AD. 
CHAPTER V 
TIME COURSE OF THE HISTOPATHOLOGICAL EFFECTS OF INJECTIONS OF AMYLOID-P 
25-35 INTO THE AMYGDALA OF YOUNG MALE FISCHER RATS 
Abstract 
To examine the time course of the histopathological effects of bilateral injections of 
amyloid-P 25-35 (AP) and to determine if these effects are associated with a reduction in 
choline acetyltransferase (ChAT) activity and behavioral impairments, we injected AP (5.0 
nmol) into the amygdala of young male Fischer rats. Control rats received vehicle infusions. 
For histological analysis, animals were sacrificed at 8, 32, 64, 96 and 1 28 days 
postoperatively (n = 21-33 per timepoint). AP induced neuronal tau-2 staining in the right 
amygdala and hippocampus but not in the same brain regions within the left hemisphere. 
AP also induced reactive astrocytosis and neuronal shrinkage within the right hippocampus 
and amygdala, respectively. As with tau-2, the same brain regions within the left 
hemisphere in the AP treated rats were significantly less affected. In addition, AP appeared 
to induce microglial and neuronal interleukin-1 p staining. The histopathological effects of AP 
peaked at 32 days postoperatively. These effects were not associated with a reduction in 
amygdaloid ChAT activity at 32 days postinjection. In a separate experiment, behavioral 
effects of bilateral intra-amygdaloid injections of AP were analyzed at 34-52 days 
postoperatively. In the open field, the treatment groups differed only in the numbers of rears 
emitted. AP treated rats emitted significantly more rears than vehicle treated rats 
(p = 0.016). There was no effect of AP in the Morris water maze or in the acquisition and 
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retention of a one-way conditioned avoidance response. These data suggest a laterality in 
the histopathological effects of A~ and that the effects of single injections are in part 
transient. These findings also suggest a direct association between plaque and tangle 
formation in Alzheimer's disease (AD), and support the use of this rat model to screen drugs 
that may alter the initial pathological events associated with AD, that occur before the 
manifestations of extensive behavioral impairments. 
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Introduction 
The histopathological characteristics of Alzheimer's disease (AD) include senile 
plaques, reactive astrocytes and microglia, neurofibrillary tangles, neuronal shrinkage and 
cell loss in several brain regions. Senile plaques consist predominantly of amyloid-P (Ap) 1-
42 (103,214,233,285). It is derived from a large membrane spanning protein, the amyloid-
p precursor protein (APP) (166), and is thought to play an important role in the pathogenesis 
of AD. Mutations in APP in some forms of familial AD ( 104,242) are associated with an 
elevated production of AP (33,39,331 ). APP is overexpressed in Down's syndrome 
(248,291) and individuals with this disease invariably develop the neuropathological 
hallmarks of AD (23, 1 87). Senile plaques appear at a younger age than do neurofibrillary 
tangles in Down's syndrome ( 100,212,291,358), suggesting that AP may have a role in 
tangle formation. The main component of neurofibrillary tangles is paired helical filaments 
( 168,335), which consist largely of the microtubule associated protein tau in an abnormal 
state of phosphorylation (171, 182,355,356). In vitro (26,207) and in vivo 
(91, 178, 180,315,317) studies have demonstrated that AP induces abnormal tau 
immunoreactivity (IR), suggesting an association between plaque and tangle formation in 
AD. The distribution of plaques and tangles in AD is such that AP deposits are often 
located at the nerve terminals of neurons that contain tangles. This suggests that AP may 
act on nerve terminals to cause cytoskeletal alterations in axons that ultimately lead to 
tangle formation within the perikarya (265). This notion is supported by the observation 
that the APP is predominantly located in the synaptic zone of neurons (301 ). 
The proposed role for AP in the pathogenesis of AD is further supported by the 
neurotoxicity of AP in vitro (369,370), that includes amino acids 25-35 of the peptide 
(370). AP toxicity in cell culture (273,284,368-370) depends on its aggregation state 
(25,220,269,273), and requires the assembly of AP into amyloid fibrils composed of a P-
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pleated sheet structure (26, 144,203). The reproducibility of Aj3 toxicity in vivo has been 
inconsistent (42,91,99, 101, 102, 178, 180,314,315,317,320,354). This may be due to 
variations in: 1) the conformational state (25,269,273), dose, and sequence of Aj3; 2) 
method of administration; 3) pathological endpoints measured; 4) what brain region and/or 
hemisphere is injected; 5) postoperative interval; and, 6) species and/or strain used. 
The transformation of resting astrocytes to reactive astrocytes is one of the earliest 
and most predominant responses of the central nervous system (CNS) to tissue injury. In 
the AD brain, reactive astrocytes are found in high abundance surrounding senile plaques 
(70, 126, 128,250). They colocalize with plaques at a relatively early stage in AD and 
apparently prior to the appearance of plaque associated dystrophic neurites (270). Glial 
fibrillary acidic protein (GFAP) (77) is a component of the glial intermediate filaments that 
form part of the cytoskeleton, and is found predominantly in astrocytes. GFAP levels in AD 
brains are increased 8 to 16 fold compared to control brains (21,60). Recent reports 
suggest that Aj3 induces reactive astrocytosis in vitro (34, 141,271) and we have 
demonstrated a similar effect in vivo (315,317). 
Microglia are the brain's representatives of the immune system and express many 
leukocyte surface antigens, which are upregulated in AD (227). In the AD brain, microglia 
are known to associate with plaques (122, 155,228), and inflammatory cytokines found in 
senile plaque regions include interleukin (IL) 1, IL-6, and tumor necrosis factor 
(62, 117,309). Microglia seems to be the major source of IL-1 within the CNS, but this 
cytokine is also found in astrocytes and neurons (300). In rat, mouse, human and other 
species, IL-1 exists in two forms, IL-1 a (199) and IL-1 j3 (9) that are the products of two 
separate genes (40,97). Human IL-1a and IL-1 j3 have 25% homology and appear to have a 
similar biological activity (63). IL-1 j3 in vitro stimulates the APP promoter (64), induces APP 
mRNA (59,89, 108), stimulates production of the secreted form of APP (31 ), and enhances 
Aj3 cytotoxicity in PC12 cells (82). Conversely, Aj3 in vitro induces IL-1 j3 mRNA in astroglial 
cells (59), enhances astro- and microglial secretion of IL-1 (4), and stimulates the 
proliferation and morphological transformation of microglia (4). 
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Relatively few studies have investigated the effects of A~ injections on behavior and 
the experimental procedures vary substantially 
(41,65,85, 102,221,223,224,244,314,334,354). Most of these studies have shown that 
intracerebral injections of A~ cause behavioral alterations, except a study using the rat A~ 
(354) and a report where A~ by itself had no effect but potentiated the behavioral 
impairments induced by ibotenic acid (65). We have also previously reported that injections 
of A~ into the basal forebrain had no significant behavioral effects (314). 
The major pathological changes in AD are in regions of the medial temporal lobe, 
including the hippocampus, amygdala, entorhinal cortex and parahippocampal gyrus (265). 
Among these brain regions, the number of senile plaques has been reported to be highest in 
the amygdala (8). Some reports indicate that the amygdala is affected earlier in the disease 
than the hippocampal or cortical areas (158,258). Previously, we have observed that single 
A~ 25-35 injections (5.0 nmol) into the right amygdala of rats produce progressive (8 vs. 32 
days) cytoskeletal and astrogliotic reactions within the amygdala, and at distant brain 
regions that project to the amygdala (317). We have also reported on the laterality in the 
histopathological effects of bilateral intra-amygdaloid injections of A~ 25-35 at 32 days 
postoperatively (315). To examine the time course of the histopathological effects of 
bilateral injections of A~ and to determine if these effects are associated with a reduction in 
choline acetyltransferase (ChAT) activity and behavioral impairments, we injected A~ (5.0 
nmol) bilaterally into the amygdala of young male Fischer-344 rats. The data for the A~ 
deposits, tau-2 IR, reactive astrocytosis and neuronal shrinkage at 32 days postoperatively 
has been previously reported (31 5). 
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Materials and Methods 
Animals 
Male Fischer-344 rats were obtained from the NIA colony at Harlan Sprague-Dawley 
(Indianapolis, IN). At the time of arrival, the rats weighed 250-300 g and were 3-4 months 
of age. The animals were housed individually, maintained on a 12 h light-dark cycle (lights 
on at 07:00 h) in a AAALAC approved facilities, had access to food and water ad libitum, 
and were habituated to their new environment for 2-3 weeks prior to surgery. 
Suraery 
Surgery was performed under sodium pentobarbital (50 mg/kg, intraperitoneally 
(i.p.); Butler, Columbus, OH) anesthesia. Atropine sulfate (0.4 mg/kg; Sigma, St. Louis, 
MO) and ampicillin sodium salt (50 mg/kg; Sigma) were injected intramuscularly once the 
animals were anesthetized. The animals received a bilateral injection of 5.0 nmol into each 
amygdala. Some of the animals were injected first into the right amygdala and subsequently 
into the left amygdala, while others were injected simultaneously into the left and right 
amygdala. A Kopf stereotaxic instrument was used with the incisor bar set at 3.3 mm 
below the interaural line. Injection coordinates measured from the bregma and the surface 
of the skull (AP - 3.0, ML ± 4.6, DV - 8.8) were empirically determined based on the atlas 
of Paxinos and Watson (261 ). A volume of 3.0 µI was administered over 6 min (flow rate 
0.5 µI/min) using a CMA/100 microsyringe pump (Carnegie Medicin AD, Solna, Sweden). 
The cannula was left in situ for 2 min following injection, and then was slowly withdrawn. 
Following surgery the animals were placed on a heating pad until they regained their righting 
reflex. 
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AP 25-35 and AP 35-25 (BACHEM, Torrance, CA) were supplied as trifluoroacetic 
acid (TFA) salts. At the time of surgery, information was not available from the supplier 
regarding the amount of TFA per mg of the salt of the peptide. According to the supplier, 
there is not a direct stoichiometric relationship between the content of AP 25-35 and TFA, 
in other words it is not known how many mol of TFA there are in each mol of the TFA salt 
of AP 25-35. The peptide content was 77% ( ± 3%) with the remaining 23% consisting of 
TFA and H20, and the purity of the peptide was > 98%. We assumed that there are 2 nmol 
of TFA per 1 nmol of AP 25-35, that is TFA content of 16.7% per mg of the salt. Recent 
information from the supplier indicates that the TFA content is actually 9.7%. The peptide 
and its respective vehicle (VEH; TFA, sodium salt; Sigma) were dissolved in Nanopure® 
water (H 20) immediately before use and stored at 4°C between injections. 
Animal Sacrifice and Tissue Preparation 
For histological analyses, animals were anesthetized with sodium pentobarbital ( 1 00 
mg/kg, i.p.), perfused transaortically at 8, 32, 64, 96 or 128 days postoperatively and the 
brains processed as previously described (317). Serial coronal sections (40 µm) were cut 
and five series of sections at 0.2 mm intervals were saved for histological analysis of 1) 
cresyl violet, 2) tau-2, and 3) GFAP staining. Also, selected series were stained with IL-1 P 
and Congo red. The first series was immediately mounted on slides, dried, and stained with 
cresyl violet. The other series were placed in ethylene glycol cryoprotectant and stored at -
20°C until used for immunohistochemistry. 
For neurochemical analysis (ChAT activity), the animals were sacrificed by 
decapitation between 09.00-15.00 h in an area outside the animal room. The brains were 
removed and dissected over ice using a modification of the method detailed by Heffner et al. 
(133). Accordingly, serial 2.0 mm coronal sections were obtained. The amygdaloid 
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complex (4.0 mm) was obtained, frozen on dry ice and stored at -80°C until assayed. 
Extensive histological analysis was not performed on the rats that were tested behaviorally 
but appropriate cannula placement and A~ deposition was verified in several animals. 
Histology 
Cresyl violet and Congo red: Mounted sections were defatted in xylene and 
hydrated in ethyl alcohol and water series. Cresyl violet staining was performed as 
previously described (317). Congo red staining was performed for 1 h in a 50% ethanol 
solution containing 1 % Congo red. The sections were then dipped in saturated lithium 
carbonate for 1 5 sec and subsequently washed in running water for 1 5 min. 
Counterstaining was performed in Harris hematoxylin for 2 min, the sections were then 
rinsed in running water, and differentiated in 1 % acid alcohol. Subsequently, the sections 
were washed in running water, dipped in ammonia water, and again washed in running 
water. The sections were then dehydrated in ethyl alcohol series and cleared in xylene. The 
tissue was subsequently covers lipped using a DePeX mounting medium. 
Tau-2 and GFAP: Staining was performed as previously described (317). Briefly, 
sections (40 µm) were incubated in tau-2 (Sigma, St. Louis, MO) primary antibody at a 
1 :500 dilution for 24 h at room temperature. An anti-mouse immunoglobulin (lg) G 
secondary antibody (Vectastain ABC Elite kit, Vector Laboratories, Burlingame, CA) was 
used at a 1 :2000 dilution. GFAP staining was performed the same way as the tau-2 
staining. The GFAP antibody (Dako, Denmark) was used at a 1 :500 dilution. The 
secondary antibody was a goat anti-rabbit lgG (Vector) diluted 1: 1333. Omit sections for 
tau-2 and GFAP were obtained by omitting the primary antibody. According to product 
specifications, the biotinylated anti-mouse lgG (Vector) has 25% cross-reactivity with rat 
lgG. We were able to reduce this non-specific staining by diluting the secondary antibody. 
lmmunolabelled neurons in the omit sections were subtracted accordingly to establish a 
baseline. 
!1.:.1..lt Performed the same way as GFAP staining. The anti-rat IL-1 ~ (Endogen, 
Cambridge, MA) was used at a 1 :250 dilution. The secondary antibody was a goat anti-
rabbit lgG (Vector) diluted 1: 1333. 
Behavioral Analyses 
Animals were handled daily beginning four days prior to the first behavioral 
experiment, and daily throughout the experiments. 
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Open Field Activity: The open field was used to measure a neophobic response and 
subsequent exploratory behavior. The dimensions of the open field were 1 00 cm x 100 cm 
x 40 cm high. The walls were composed of varnished plywood. The floor was painted flat 
white and divided by thin black lines into 25 squares (20 x 20 cm). Four equidistantly 
spaced holes (3.5 cm diameter) were located in the four corner squares of the central nine 
squares. The open field was located in a sound-attenuated dark room and was illuminated 
by two 15 W fluorescent tubes positioned adjacent to the chamber, as well as by a 25 W 
fluorescent tube located under the elevated (7. 5 cm) floor of the chamber. The animals 
were placed in the open field for 1 2 min and their behavior analyzed by means of a video 
monitor. The following behaviors were quantified: ( 1) the time to leave the center squares, 
(2) the number of wall and center squares entered, (3) the number of rears, (4) the number 
of nose pokes, and (5) the number of fecal boli. 
One-Way Conditioned Avoidance Response !CAR): One-way avoidance conditioning 
is a spatial (place) learning and memory task that is motivated by an aversive unconditional 
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stimulus. The chamber was comprised of two identical compartments (50 cm long, 24 cm 
wide, and 30 cm high) separated by a 7.0 cm high serrated metal hurdle (0.5 mm thick). 
The ceiling, rear, and end walls were composed of white opaque plastic (Perspex) whereas 
the front wall was made of transparent Perspex. The grid floor consisted of stainless steel 
rods (3.0 mm diameter) spaced 1.0 cm apart. Illumination was provided by a 25 W 
fluorescent tube mounted outside the rear wall. A Grason-Stadler control panel and shock 
generator were used to deliver scrambled continuous constant-current (0.8 mA) shock. 
Each animal was placed in the apparatus, close to and facing the end wall of the 
"shock" compartment. After a delay of 5.0 sec, continuous shock was delivered until the 
rat crossed the hurdle and entered the opposite side of the apparatus (the "safe" 
compartment). If a rat failed to escape the shock within 15 sec, it was placed in the safe 
compartment. The animal was left undisturbed for 20 sec, unless it returned to the "shock" 
compartment. If so, shock was delivered until the rat re-entered the "safe" compartment. 
After spending 20 sec in the "safe" compartment, the rat was removed from the apparatus 
and placed in its home cage for 5.0 sec, before the start of the next trial. Crossing the 
hurdle within 5.0 sec after placement in the "shock" compartment was scored as an 
avoidance response. Response latency was measured automatically by an elapsed timer. 
Testing was continued until criterion (9 avoidance responses in 10 consecutive trials) was 
attained. If a rat returned within 20 sec to the "shock" compartment after having made a 
CAR, the preceding CAR was not included as one of the criterion trials. Failure to enter the 
"safe" compartment before shock was delivered and returns to the shock compartment were 
scored as errors. All the rats reached criterion in a single session. 
Retention of the one-way CAR task was examined 2 weeks later. The rats were 
treated in the same manner as during the acquisition phase and tested until criterion was 
attained. 
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Morris Water Maze: Spatial learning and memory were tested in the Morris water 
maze task. The maze consisted of a circular plastic tub (152 cm in diameter and 74 cm 
deep), painted flat white. A platform (9 cm in diameter) was placed halfway between the 
center of the pool and the edge, 1.5 cm below the surface of the water. The water (56 cm 
deep) in the pool was made opaque by the addition of powdered milk, and its temperature 
was 19-21 °C. Extra maze cues were plentiful and kept consistent throughout the entire 
experiment. Data was gathered with a video tracking system (Chromotrack 3.01 a, San 
Diego Instruments, San Diego, CA). A small video camera linked to a computer was 
mounted directly over the center of the maze. A small black dot was painted on the 
animal's head with a non-toxic marker because the camera visualizes a dark object on a light 
field. The computer calculated the animal's path length to platform and the latency to find 
the platform. 
The animals were given 4 trials a day for 5 consecutive days, or a total of 20 trials. 
On each trial the animal was placed into the pool close to the edge in the middle of a 
quadrant. The first 4 days, the platform was located in the same quadrant. The 5th day, 
the platform was moved to the opposite quadrant. On the first trial the animal was placed 
into the pool in a quadrant next to the platform. In the 3 subsequent trials the animals were 
placed into the pool in the adjacent quadrants in a clockwise manner. A trial continued until 
the animal climbed onto the platform, or until 60 sec had elapsed. It was left on the 
platform for 60 sec prior to the start of the next trial. Upon completion of all four trials the 
rat was removed from the maze, dried with a towel and returned to its cage. 
Neurochemical Analysis 
Frozen brain tissue (-80°C) was weighed, thawed at 4°C and homogenized in ice-
cold sodium phosphate buffer (75 mM, pH 7.4). ChAT activity was measured using a 
modification of the method of Fonnum (86). Briefly, 10 µI of homogenate were added to 10 
101 
µI of buffer substrate mixture. The mixture contained 49 volumes of buffer substrate 
(sodium phosphate, 75 mM, pH 7.4; NaCl, 600 mM; MgCl2 , 40 mM; eserine, 2.0 mM; 
bovine serum albumin, 0.05%; choline iodide, 10 mM; and acetyl-CoA, 0.87 mM) and 1 
volume of [3 H]acetyl-CoA (200 mCi/mmol, 0.5 mCi/ml; Du Pont NEN®, Boston MA). The 
samples were incubated for 30 min at 37°C, and then placed on ice. Newly synthesized 
radiolabelled acetylcholine (ACh) was extracted into 1 50 µI of sodium tetraphenylboron 
solution (75 mg/ml in 3-heptanone). The tubes were vortexed and after centrifugation, 100 
µI of the organic layer were taken to measure [3HJACh using liquid scintillation spectrometry. 
The amount of radioactivity extracted from buffer, incubated in parallel, without tissue, was 
subtracted as blank. Activities were measured in triplicates. Protein measurements, in 
duplicates, were performed according to Lowry et al. (204). 
Data Analysis 
An image analysis system (NIH Image 1 .49) was used to determine the size of the 
A~ deposits and neuronal shrinkage within the left and right amygdala at different 
timepoints. The area of the A~ deposits was measured at 0.2 mm intervals. These data 
failed a normality test and were, therefore, analyzed by a two-way analysis of variance 
(ANOVA) on ranks (SIGMASTAT, version 1.01; Jandel, San Rafael, CA) followed by a 
Newman-Keuls' multiple range test for post hoc comparisons. Quantitative analysis was 
performed on the cresyl violet stained sections at 32 and 1 28 days postinjection. The 
basolateral nucleus within the amygdala can be divided into parvicellular and magnocellular 
subnuclei based on the cytoarchitecture of the neurons. The cells within these subnuclei 
have a relatively uniform appearance and their boundaries are easily identified. The 
magnocellular division is located mainly rostral and medial to the parvicellular division. The 
area of 1 O of the largest magnocellular cells (X400 magnification) within the left and right 
basolateral amygdala was measured in one cresyl violet stained section per animal slightly 
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rostral to the injection site, and we carefully chose sections at a similar coronal level. The 
average area of these 10 cells was calculated. The data based on this average cell area 
failed a normality test and were, therefore, analyzed by a two-way ANOV A on ranks 
followed by a Newman-Keuls' multiple range test for post hoc comparisons. Neuronal tau-2 
IR in the left and right amygdala and hippocampus, and reactive astrocytosis in the left and 
right hippocampus were rated on a scale of 0-2 +. An animal was considered positive if it 
exhibited ~ 1 + staining. These data were analyzed using a Fisher exact test, one-tail 
(SIGMASTAT). No statistical difference was discerned between the VEH groups at each of 
the timepoints so they were combined in the subsequent analysis. The rating of the tau-2 
sections was based on the number of IR cells (X400 magnification), relative to omit 
sections, within the amygdala or hippocampus in a section at the injection site (0 = 0-5 
cells/section; 1 + = 6-50 cells/section; 2 + = > 50 cells/section). The brain region that had 
higher cell counts was used for analysis. We have previously demonstrated (315) that there 
is a significant correlation between the number of tau-2 IR neurons within the amygdala and 
hippocampus (r=0.833, p<0.001). The rating of the GFAP sections was based on the 
complexity of astrocytic branching within the hippocampus (0 =resting astrocytes, few 
processes; 1 + = reactive astrocytes, moderate branching; 2 + = reactive astrocytes, 
extensive branching). In addition, a more detailed analysis of tau-2 IR was performed at 32 
and 128 days postoperatively. Tau-2 IR neurons were counted in the left and right 
amygdala in six sections surrounding the injection site, and in six hippocampal sections 
including and caudal to the injection site. Tau-2 IR neurons were also counted in omit 
sections and subtracted accordingly. These data failed a normality test and, therefore, were 
analyzed using a two-way ANOVA on ranks for the amygdala and hippocampus separately, 
followed by a Newman-Keuls' multiple range test for post hoc comparisons. No statistical 
difference was discerned, in any of the parameters analyzed, between rats injected first into 
the right and subsequently into the left amygdala, and animals injected simultaneously into 
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the left and right amygdala, so they were combined in the subsequent analyses. The open 
field and the CAR data were analyzed by a t-test or a Mann-Whitney rank sum test when the 
data failed a normality test (SIGMASTAT). The Morris water maze data, when the platform 
was in its original position, was analyzed by a two-way ANOV A with repeated measures on 
one factor (days) followed by a Newman-Keuls' post hoc test (SIGMASTAT). At-test was 
used to analyze the water maze reversal data. The ChAT activity data was analyzed by a 
two-way ANOV A on ranks because the data failed a normality test. 
Experimental Design 
Experiment 1: Histological effects of A~ 25-35 at 8, 32, 64, 96 and 128 days 
postoperatively. The rats were injected first into the right amygdala and subsequently into 
the left amygdala, or simultaneously into the left and right amygdala. The dose of AP 25-35 
was 5.0 nmol/3.0 µI H20 (each side). VEH treated animals were injected with 10.0 nmol 
TFA/3.0 µI H20 (each side). 
Group# n Days Treatment 
9 8 VEH 
2 12 8 AP 25-35 
3 13 32 VEH 
4 20 32 AP 25-35 
5 13 64 VEH 
6 19 64 AP 25-35 
7 11 96 VEH 
8 16 96 AP 25-35 
9 11 128 VEH 
10 17 128 AP 25-35 
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Experiment 2: Behavioral effects of bilateral intra-amygdaloid injections of Aj3 25-35 
at 34-52 days postoperatively. The same dose was used as in Experiment 1 (5.0 nmol/3.0 
µI). 
Group# 
2 
n 
10 
13 
Treatment 
VEH 
Aj3 25-35 
Experiment 3: Effects of bilateral intra-amygdaloid injections of Aj3 25-35 (5.0 
nmol/3.0 µI) on ChAT activity in the amygdala at 32 days postinjection. 
Group# 
2 
3 
n 
5 
5 
6 
Treatment 
VEH 
Aj3 35-25 
Aj3 25-35 
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Results 
Experiment 1: Histological Effects of AB 25-35 at 8. 32. 64. 96 and 128 Days 
Postoperatively. 
AB deposits 
Proteinaceous deposits were observed bilaterally in the amygdala of the AJ3 25-35 
rats (Figures 16, 17). The location of the deposits did not vary between the left and right 
amygdala. The deposits were found consistently at the injection site immediately medial to 
the basolateral nucleus. The size of the deposits appeared to be less than the overall 
volume of the basolateral nucleus. These deposits were Congo red positive (apple-green 
birefringence under polarized light) similar to those we have observed following AJ3 25-35 
injections into the ventral pallidum/substantia innominata (VP/SI) (314), and into the right 
amygdala (317). These deposits were seen in animals at all timepoints (8-128 days; Figure 
17). Ninety percent of the injections resulted in AJ3 deposits at the time of sacrifice. Two-
way ANOV A of the area of these deposits within the left and right amygdala at different 
timepoints revealed a significant difference between the left and right amygdala [F( 1, 
158) = 5.261, p =0.0231 but there was no difference between timepoints [F(4, 
158) = 1.774, p =0.137], and no interaction between the two factors [F(4, 158) = 1.013, 
p = 0.402]. Also, post hoc pairwise comparisons between these two factors revealed no 
significant differences (Figure 17). 
Figure 16. Congo red positive AJ3 deposits at 32 and 128 days postoperatively. Congo red 
stained coronal sections (X160) through the left amygdala at the injection site in AJ3 25-35 
treated rats at 32 days (A) and at 128 days (B) postoperatively. Note the Congo red 
positive birefringence under polarized light in the AJ3 deposits at both 32 and 1 28 days 
postinjection. 
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Figure 17. Size of the A~ deposits within the left and right amygdala at 8, 32, 64, 96, and 
128 days postoperatively. These deposits were Congo red positive (apple-green 
birefringence under polarized light). Post hoc analysis of the area of these deposits within 
the left and right amygdala at individual timepoints revealed no significant differences. Each 
bar represents the mean+ SEM of n = 12-20 rats. LDEP: A~ deposits, left amygdala; RDEP: 
A~ deposits, right amygdala. 
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A semi-quantitative analysis revealed an increase in tau-2 staining that was observed 
predominantly within the right amygdala or hippocampus in the A/3 infused rats at 8 days 
(p<0.01), 32 days (p<0.001) and 64 days (p<0.01) postinjection, compared to the VEH 
treated rats (Figures 18, 19). A/3 25-35 increased tau-2 IR in neuronal perikarya and 
processes predominantly in the right amygdala and hippocampus. There also appeared to be 
an increase in tau-2 IR in other brain areas within the right hemisphere, such as the 
cingulate, parietal and pyriform cortices, hypothalamus, thalamus, globus pallidus, 
claustrum, substantia nigra, VP/SI, and the entorhinal cortex. These cytoskeletal changes 
peaked at 32 days postinjection (Figure 19). The left amygdala and hippocampus were 
significantly less affected in the VEH treated animals (p<0.01 ), and the A/3 treated rats at 8 
days (p < 0.05), 32 days (p < 0.001), and 64 days (p < 0.01) postoperatively. 
A quantitative analysis at 32 and 128 days postoperatively revealed a similar effect 
as the semi-quantitative analysis. Two-way ANOVA for the amygdaloid tau-2 IR (Figure 
20A) revealed a significant difference between rats sacrificed at 32 days vs. 128 days [F(1, 
112) = 6.195, p < 0.014], and between treatments and/or hemispheres [F(3, 112) = 19.234, 
p < 0.001]. There was also a significant interaction between the two factors [F(3, 
112) = 5.306, p = 0.002]. Post hoc pairwise comparisons between the two factors revealed 
a significant difference at 32 days between the left and right amygdala in the A/3 treated rats 
(p<0.01) and in the right amygdala between the VEH and A/3 treated rats (p<0.01). Also, 
in the A/3 infused rats the number of tau-2 IR neurons within the right amygdala differed at 
32 days vs. 128 days postoperatively (p<0.01 ). A similar pattern was observed within the 
hippocampus (Figure 208). Two-way ANOVA for the hippocampal tau-2 IR revealed a 
significant difference between rats sacrificed at 32 days vs. 128 days [F(1, 112) = 4.910, 
p < 0.029], and between treatments and/or hemispheres [F(3, 112) = 8. 701, p < 0.001]. 
There was also a significant interaction between the two factors [F(3, 112) = 5.248, 
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p = 0.002]. Post hoc pairwise comparisons between the two factors revealed a significant 
difference at 32 days between the left and right hippocampus in the A~ treated rats 
(p<0.01) and in the right hippocampus between the VEH and A~ infused rats (p<0.01 ). 
Also, in the A~ treated rats, the number of tau-2 IR neurons within the right hippocampus 
differed at 32 days vs. 128 days postoperatively (p < 0.01). 
Figure 18. Tau-2 IR at 32 days postinjection. Tau-2 stained coronal section through the left 
(A) and right (C) hippocampus (X63), and the left (8) and right (D) amygdala (X63) in a rat 
injected bilaterally with A~ 25-35. E (X160) and F(X250) are magnifications of the areas 
bracketed in C and D, respectively. The hippocampal sections are substantially caudal ( 1. 5 
mm) to the injection site. The amygdaloid sections are at the injection site, where A~ 
deposits (arrows in B and D) are visible. No tau-2 IR is observed within the left 
hippocampus (A) or the left amygdala (8). Note the neuronal tau-2 IR within the right 
hippocampus (C, E) and the right amygdala (D, F) in this same animal. This rat represents a 
rating of 0 in the left hippocampus and amygdala, and a rating of 1 + in the right 
hippocampus and amygdala. 
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Figure 19. Time course of neuronal tau-2 IR within the left and right amygdala or 
hippocampus. Note the transient induction in tau-2 IR within the right amygdala or 
hippocampus in the A~ treated rats. Note the lack of AP effect within the left hemisphere 
compared to the right hemisphere. No statistical difference was discerned between the VEH 
groups at each of the timepoints (n = 9-13) so they were combined (n = 58) in the 
subsequent analysis. The bars for the AP treated rats represent n = 12-20. The data are 
presented as the percentage of positive rats (rating of ~1 +) of total rats analyzed. Effects 
of AP in the right amygdala or hippocampus compared to VEH treated rats: * *p < 0.01; 
* * * p < 0.001. Effects in the right amygdala or hippocampus compared to the left amygdala 
or hippocampus: #p<0.05; ##p<0.01; ###p<0.001. 
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Figure 20. Neuronal tau-2 IR within the left and right amygdala (A) and hippocampus (B) at 
32 and 128 days postinjection. Each bar represents the mean+ SEM of tau-2 IR neurons 
from 6 sections (40 µm). The bars for the VEH treated rats at 32 and 1 28 days represent 
n = 1 3 and 11, respectively. The bars for the A~ treated rats at 32 and 1 28 days represent 
n = 1 9 and 17, respectively. Effects of A~ at 32 days in the right amygdala or hippocampus 
compared to VEH treated rats: * * p < 0.01. Effects of A~ at 32 days in the right amygdala 
or hippocampus compared to the left amygdala or hippocampus: ##p < 0.01. Effects of A~ 
in the right amygdala or hippocampus at 32 vs. 128 days: A Ap<0.01. 
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Reactive astrocytosis (Figures 21, 22) was observed predominantly within the right 
hippocampus in the AP treated rats at 8 days (p<0.001), 32 days (p<0.001 ), 64 days 
(p < 0.01), and 96 days (p < 0.05) postinjection, compared to VEH treated rats. The left 
hippocampus was significantly less affected in the VEH treated animals (p < 0.01 ), and the 
AP treated rats at 8 days (p<0.01), 32 days (p<0.001), and 64 days (p<0.01) 
postoperatively. These histological changes peaked at 32 days postoperatively, and were 
seen most consistently within the right hippocampus although other areas of the right 
hemisphere appeared to be also affected. 
Figure 21. GFAP IR at 32 and 128 days postinjection. GFAP stained coronal sections 
(X25) through the left (A) and right (8) hippocampus in a bilaterally injected AP 25-35 rat at 
32 days postoperatively, and through the right hippocampus (C) in a bilaterally treated AP 
25-35 rat at 128 days postinjection. D represents the right hippocampus in a VEH treated 
rat at 32 days postoperatively. E, F, G, and H are magnifications of the areas bracketed in 
A, 8, C, and D, respectively. Reactive astrocytosis is moderate in the left hippocampus (A, 
E), whereas prominent reactive astrocytosis is observed in the right hippocampus (8, F). No 
effect is observed in the AP 25-35 treated rat at 128 days (C, G) or in the VEH treated rat 
(D, H). The AP 25-35 infused rat at 32 days postinjection represents a rating of 1 + in the 
left hippocampus and a rating of 2 + in the right hippocampus. The AP 25-35 treated rat at 
1 28 days postinjection and the VEH injected rat at 32 days postoperatively represent a 
rating of 0 in the right hippocampus. 
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Figure 22. Time course of reactive astrocytosis within the left and right hippocampus. Note 
the transient induction in reactive astrocytosis within the right hippocampus in the Af3 
treated rats. Note the lack of Af3 effect within the left hippocampus compared to the right 
hippocampus. No statistical difference was discerned between the VEH groups at each of 
the timepoints (n = 9-13) so they were combined (n = 58) in the subsequent analysis. The 
bars for the Af3 treated rats represent n = 12-20. The data are presented as the percentage 
of positive rats (rating of ~1 +) of total rats analyzed. Effects of Af3 in the right 
hippocampus compared to VEH treated rats: *p<0.05; **p<0.01; ***p<0.001. Effects 
in the right hippocampus compared to the left hippocampus: ##p < 0.01; ###p < O.b01. 
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Cresyl violet (CV) 
All nuclei within the right amygdala appeared to be shrunken in the A~ treated rats 
but the atrophy was most obvious in the large magnocellular neurons within the basolateral 
amygdala (Figure 23). A quantitative analysis was performed at 32 and 128 days 
postinjection of the area of 1 0 of the largest magnocellular cells within the basolateral 
amygdala (Figure 24). Two-way ANOVA revealed a significant difference between rats 
sacrificed at 32 days vs. 128 days [F( 1, 114) = 43.480, p < 0.001], and between treatments 
and/or hemispheres [F(3, 114) = 13.664, p < 0.001]. There was not a significant interaction 
between the two factors [F(3, 114) = 2.332, p<0.078]. Post hoc pairwise comparisons 
between the two factors revealed a significant difference at 32 days between the left and 
right amygdala in the A~ treated rats (p < 0. 01 , 33 % reduction in average cell area) and in 
the right amygdala between the VEH and A~ treated rats (p<0.01, 30% reduction). Also, 
in the A~ treated rats the cell area at 32 days vs. 1 28 days differed in the left (p < 0. 01 ) and 
right amygdala (p < 0.01 ). Furthermore, in the A~ injected rats at 128 days the cell area 
within the right amygdala (13% reduction) differed from that in the left amygdala (p<0.05). 
The neuronal atrophy appeared to extend into other brain regions within the right 
hemisphere, such as cortical areas. Cell bodies within the hippocampus overlapped and, 
therefore, analysis of cell shrinkage was not performed in that brain region. The A~ induced 
neuronal shrinkage did not appear to be associated with extensive neuronal loss. 
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Figure 23. Cresyl violet staining at 32 days postinjection. Cresyl violet stained coronal 
section (X63) through the left (A) and right (B) amygdala slightly rostral to the injection site 
in a bilaterally injected A~ rat, at the level of cell area measurements. C and D are 
magnification (X250) of the areas bracketed in A and B, respectively . Note the neuronal 
shrinkage within the right (B, D) as compared to the left basolateral nucleus (A, C). In this 
animal, the average area of 10 of the largest magnocellular cells was 1 986 ± 1 87 (SD) in the 
left nucleus, and 1016 ± 178 in the right nucleus. 
118 
3000 
2500 
.,.. /\/\ 
-C\J D VEH LAMY E 2000 
::1. 
_. D VEH RAMY 
m 1500 (l) 
lo.... 
<( 
a A~ LAMY 
(l) 1000 () 
~ A~ RAMY 
500 
0 
32 128 Days 
Figure 24. Neuronal shrinkage in cresyl violet stained sections within the right amygdala vs. 
the left amygdala at 32 and 128 days postoperatively. Each bar represents the mean + SEM. 
The bars for the VEH treated rats at 32 and 128 days represent n = 13 and 11, respectively. 
The bars for the A~ treated rats at 32 and 128 days represent n = 20 and 1 7, respectively. 
Note the neuronal shrinkage within the right but not the left amygdala in the A~ treated rats 
at 32 days and the partial reversibility of the effect of A~ at 128 days postinjection. Effects 
of A~ in the right amygdala compared to VEH treated rats: * *p < 0.01. Effects of A~ in the 
right amygdala compared to the left amygdala: #p<0.05; ##p<0.01. Effects of A~ in the 
left and right amygdala at 32 days vs. 128 days: A A p < 0.01. 
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IL-1 ~ IR was predominantly observed in microglia but a less intense neuronal 
staining also was evident (Figure 25, 26). The microglia were seen in the vicinity of the 
cannula track, particularly at the injection site within the amygdala. Microglia were also 
prominent in the alveus and the molecular layer of the left hippocampus, and in the 
ependymal lining of the ventricles. In the A~ injected rats, these microglia surrounded and 
infiltrated the A~ deposits bilaterally in the amygdala. Reactive microglia appeared to be 
more prominent within the left than the right hippocampus at 8 and 32 days postoperatively 
in the A~ treated animals. Laterality also was observed in neuronal IL-1 ~ staining. Neuronal 
staining appeared to be minimal in VEH treated rats. In A~ treated rats, there appeared to 
be an evenly distributed induction in neuronal IL-1 ~ staining within the left amygdala and 
hippocampus. Minimal neuronal staining was observed within the right amygdala in the A~ 
treated rats but several neuronal perikarya stained intensely within the right hippocampus. 
Further, the pattern of the most intensely IL-1 ~ stained neurons within the right 
hippocampus appeared to be similar to that of tau-2. 
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Figure 25. Amygdaloid IL-1 j3 IR at 32 days postinjection. Coronal sections (X25) through 
the injection site in the left (A) and right (8) amygdala in an Aj3 25-35 treated rat, and 
through the right amygdala in a VEH treated rat (C). Aj3 deposits are visible in A and 8 
(arrows), and the injection site in a VEH treated rat is visible in C (arrow). D, E, and Fare 
magnifications (X160) of the areas bracketed in A, 8, and C, respectively. Intense 
microglia-like IR (arrows in D and E) is observed surrounding and infiltrating the Aj3 deposits 
both within the left (A, D) and right (8, E) amygdala. Note the more intense neuronal 
staining within the left amygdala (arrowheads in D), than in the right amygdala (arrowheads 
in E). Very little IL-1 j3 IR is observed in the VEH treated rat, except for a few microglia-like 
processes (arrow in F) at the tip of the injection site. 
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Figure 26. Hippocampal IL-113 IR at 32 days postinjection. Coronal sections (X63) at the 
level of the injection site in the left (A) and right (8) hippocampus in an Aj3 25-35 treated 
rat, and in the right hippocampus in a VEH treated rat (C). D, E, and Fare magnifications 
(X250) of the areas bracketed in A, 8, and C, respectively. In the Aj3 25-35 treated rat, 
intense microglia-like IR (arrow in A) is observed in the alveus and the molecular layer of the 
left hippocampus (A) but not the right hippocampus (8). Also, moderate and evenly 
distributed induction in neuronal staining is observed within the left hippocampus (A, D) that 
is associated with microglia (arrow in 0). More intense (arrow in E) unevenly distributed 
neuronal staining is observed within the right hippocampus (8, E). Minimal IL-113 IR-is 
observed in the VEH treated rat (C, F). 
Experiment 2: Behavioral Effects of Bilateral Injections of AB 25-35 34-52 Days 
Postoperatively. 
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Animals were injected bilaterally into the amygdala with A~ 25-35 (5.0 nmol/3.0 µI; 
n = 13) or its respective VEH (3.0 µI; n = 10). Behavior in the open field (Figure 27 A, B) and 
the acquisition of a one-way (spatial) CAR were analyzed 34-38 days postoperatively. 
Retention of the CAR was performed 2 weeks after initial testing (Table 1 ). In addition, the 
rats were tested in the Morris water maze 40-46 days postoperatively (Figure 28A, B). The 
animals were sacrificed at 58 days postinjection. Extensive histological analysis was not 
performed but appropriate cannula placement and the existence of A~ deposits was verified 
in several animals. 
There was no significant difference between the treatment groups in the number of 
center squares [VEH = 6.2 ± 1.4 (SEM); A~= 10.8 ± 2.2; p =0.119], wall squares 
[VEH=46.1 ±11.8; A~=74.5±12.0;p=0.112], or total squares [VEH=52.3±12.9; 
A~= 85.4 ± 13.0; p = 0.091] entered. Also, no significant difference was observed in the 
time (sec) to leave the center squares [VEH = 41.0±11 .6; A~= 25.9 ± 6.8; p > 0.1], the 
number of nose pokes emitted [VEH = 4.9 ± 0.8; A~= 6.1 ± 1.1;p=0.419], or the number of 
fecal boli [VEH = 2.1±0.8; A~= 1.2 ± 0.3; p =0.532]. However, there was a significant 
difference in the numbers of rears emitted [VEH = 12.8 ± 2.3; A~= 21.4 ± 2.3; p = 0.016]. 
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Figure 27. Behavior in the open field ( 12 min). Each bar represents the mean+ SEM. (A) 
Bilateral injections of A~ 25-35 (5.0 nmol) into the amygdala did not cause a significant 
difference in the number of center squares, wall squares, or total squares entered, when 
compared to VEH group. (8) There was a significant difference between the treatment 
groups in the numbers of rears emitted (*p =0.016), but not in the number of nose pokes 
emitted. 
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The one-way CAR acquisition did not reveal significant differences between the 
treatment groups in the latency (sec) of the first escape, in the number of trials required for 
the first CAR, in the number of trials to reach criterion, or in the number of errors committed 
(Table 1 ). Also, no treatment effect was observed in the retention of the one-way CAR. 
Treatment Latency of Trial number Number of Number of 
the first of the first trials to errors 
escaQe (sec) CAR reach committed 
Acquisition criterion 
VEH 4.8± 1.4 4.9 ±0.5 15.0±0.4 5.8±0.3 
AP 25-35 4.9 ±0.9 3.8±0.5 15.5±0.7 5.7±0.3 
Retention 
VEH 2.9±1.0 1.1 ±0.1 10.9 ±0.3 1.8±0.2 
AP 25-35 1.4±0.2 1.2±0.1 11.8±1 .0 1.9 ±0.3 
Table 1. One-way CAR acquisition and retention. The rats received bilateral intra-
amygdaloid injections of AP 25-35 (5.0 nmol/3.0 µI). Retention was examined two weeks 
following the acquisition. The data are presented as group means± SEM. 
In the water maze there was no treatment effect. There was a time effect [time to 
find platform: F(3, 60) =49.505, p < 0.001; distance swum to platform: F(3, 60) = 39.088, 
p < 0.001]. In addition, a treatment x days interaction was close to being significant in the 
animals' path length swum to platform [F(3, 60) = 2. 708, p = 0.0531 but not in the animals' 
latency to find the platform [F(3, 60) = 1.655, p =0.186]. No difference in swim speed was 
observed between the treatment groups (data not shown). 
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Figure 28. Behavior in the Morris water maze. Each point represents the mean+ or -SEM 
of n = 10-13. The first 4 days, the platform was located in the same quadrant. The 5th 
day, the platform was moved to the opposite quadrant. Bilateral injections of A~ 25-35 (5.0 
nmol) into the amygdala did not cause a significant difference in the latency to find the 
platform (A) or in distance traveled to the platform (8), when compared to VEH group. 
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Experiment 3: Effects of Bilateral lntra-Amyqdaloid Injections of AB 25-35 (5.0 nmol/3.0 µI) 
on ChA T Activity in the Amygdala at 32 Days Postoperatively. 
Two-way ANOVA did not reveal significant differences in ChAT activity between 
treatment groups or hemispheres, or a significant interaction between the two factors (Table 
2). 
Treatment 
VEH 
A~ 35-25 
A~ 25-35 
ChA T Activity (nmol ACh/h/mq protein) 
Left Amyqdala 
107.0 ± 6.0 
110.1±5.8 
107.0±5.1 
Right Amygdala 
107.2±7.3 
109.0±4.0 
106.6 ± 5.6 
Table 2. Amygdaloid ChAT activity. The rats received bilateral intra-amygdaloid injections 
of A~ 25-35 (5.0 nmol/3.0 µI), A~ 35-25 (5.0 nmol/3.0 µI) or their respective vehicle, and 
were sacrificed 32 days postoperatively. The data are presented as group means ± SEM. 
127 
Discussion 
We have confirmed our previous finding (317), that intra-amygdaloid injection of AP 
25-35 induces neuronal cytoskeletal changes and reactive astrocytosis within the amygdala 
as well as at distal sites. In addition, these changes were associated with neuronal 
shrinkage and alterations in IL-1 p IR. Furthermore, the histopathological effects of AP 25-35 
were in part transient, and were predominantly observed within the right amygdala and 
hippocampus whereas the same brain regions in the left hemisphere were significantly less 
affected. 
We have previously discussed the relevance of the distal histological effects of AP 
25-35 to the etiology of AD (317). We have also elaborated previously on the correlation 
between the laterality effects of AP 25-35, and hemispheric asymmetries in the 
histopathological hallmarks, cerebral metabolism, and perfusion in AD (315). 
The cytoskeletal changes observed following intra-amygdaloid injections of AP 25-35 
were associated with neuronal shrinkage and reactive astrocytosis. This may simulate the 
initial histopathological changes that occur in AD, and suggests a direct association between 
plaque and tangle formation in AD. Reactive astrocytosis is a consistent response to 
neurotoxic insults, and has been observed to reveal dose, time, and region dependent 
patterns of neurotoxicity at toxicant dosages below those that cause light microscopic 
evidence of cell loss or damage (255). Our findings support this because reactive 
astrocytosis appeared to be a more sensitive marker of toxicity than tau-2 IR and neuronal 
shrinkage although the extent, regional distribution, and reversal of these histological effects 
appeared to be comparable using these three different markers. 
Microglia appear to be the major source of IL-1 within the CNS, but this cytokine is 
also found in astrocytes and neurons (300). AP 25-35 in vitro induces IL-1 P mRNA in 
astroglial cells (59). AP 1-42 enhances in vitro astro- and microglial cell secretion of IL-1, 
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and stimulates the proliferation and morphological transformation of microglia (4). These in 
vitro findings are in accordance with the intense IL-1 p glial staining surrounding and 
infiltrating the AP deposits bilaterally within the amygdala. This observation correlates with 
the association of senile plaques in AD with IL-1 positive microglia (62, 117,309). Laterality 
in IL-1 P IR was predominantly observed in neurons. Neuronal staining was minimal in VEH 
treated rats but in AP treated rats there appeared to be an induction in neuronal IL-1 p IR 
within the left hippocampus and amygdala that seemed to be rather evenly distributed within 
the neurons. In the right hemisphere in AP injected rats, intense neuronal IL-1 p IR was 
predominantly observed in hippocampal neuronal perikarya. Peptidergic neurotransmitters 
are always synthesized in the cell bodies and then transported to the nerve terminals. 
Inhibitors of axonal transport such as colchicine are often used to visualize peptide IR cell 
bodies in animal brains. Because AP 25-35 induces cytoskeletal changes it may attenuate 
the axonal transport of IL-1 P and presumably other peptides. This leads to accumulation of 
IL-1 p within neuronal cell bodies and a concomitant loss of staining in other neuronal 
compartments, which is what our results indicate within the right hippocampus. This 
hypothesis is supported by the observation that in adjacent sections from the same animal, 
the pattern of hippocampal neuronal IL-1 p and tau-2 staining appeared similar. However, 
double labeling of neurons with antibodies against IL-1 p and tau-2 would be necessary to 
verify this scenario. This presumed reduction in neuronal IL-1 p release may exacerbate AP 
toxicity because IL-1 P attenuates excitatory amino acid induced neurodegeneration in vitro 
(323), and AP potentiates in vitro neurotoxicity of excitatory amino acids (218). This 
scenario also suggests that the apparent induction in neuronal IL-1 P synthesis within the left 
amygdala and hippocampus may attenuate AP toxicity within these brain regions. 
Congo red positive AP deposits were consistently observed at the site of injection, 
suggesting that these deposits retain their p-pleated sheet structure, the toxic conformation 
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of AP, several months following injection into the rat amygdala. The AP deposits were 
extremely resistant to degradation because volumetric analysis did not reveal significant 
reduction in their size up to 128 days postinjection (Figure 17). It has been demonstrated in 
vitro, that AP develops protease resistance to degradation when polymerized into fibrils 
(252). Microglia in culture scavenge AP (5) and microglia-like phagocytes have a role in AP 
clearance following intraventricular infusions of AP 1-40 (92). Microglial activation takes 
place in a rather stereotypic pattern where there is a transformation of resting microglia into 
activated cells, which in their end stage resemble phagocytic cells. We did not observe 
phagocytic IL-1 p positive microglia, supporting the findings from the quantitative 
measurements that the amygdaloid AP deposits are resistant to proteases that are necessary 
to cleave large peptide fragments for phagocytosis to occur. The consistency and 
persistence of AP deposits likely depends on several factors, such as the method of 
administration, solvent, dose, volume, sequence of Ap, and brain region injected. The 
presence of heparan sulfate proteoglycans has been shown to be important for consistent in 
vivo deposition of AP 1-40 and persistence of fibrillar AP in the rat hippocampus (321). 
Furthermore, AP 25-35 deposits within the rat nucleus basalis have been reported to be 
degraded more rapidly than AP 1-40 deposits ( 102). Acetylcholinesterase (AChE) has been 
demonstrated to promote the formation of and/or stabilize AP fibrils ( 1 50). This proposed 
role of AChE may explain the consistency and persistence of the AP fibrils in the present 
study, because the basolateral amygdala adjacent to the injection site contains very high 
levels of AChE (261). Analysis of variance revealed that overall the size of the AP deposits 
was greater on the left than on the right side (p =0.023), suggesting that there may be 
hemispheric differences in the degradation and/or fibril formation of AP. However, post hoc 
comparison of the size of the deposits at each of the postoperative intervals investigated 
failed to reveal any significant differences. Therefore, these findings suggest that the 
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laterality and the partially transient effects of AP can not be explained by differences in the 
size of the AP deposits per se at any individual timepoint. 
The histopathological effects of AP 25-35 peaked at 32 days postoperatively. This 
indicates that the effects of single injections are in part transient even though the AP 
deposits are resistant to degradation. Chemically induced gliosis has been shown to be 
often transient in nature with the time course of both the onset and decline in GFAP varying 
markedly from toxicant to toxicant (256). The AP deposits were always surrounded by 
reactive microglia and astrocytes. It is likely that this encapsulation renders the deposits 
biologically inert. The histological effects of AP are, therefore, likely to be initiated early 
following injection, and an inflammatory response triggered by glial activation in the vicinity 
of the deposits may have a role in AP induced pathology. However, it should be noted that 
reactive glia were also associated with the cannula scar in VEH treated rats. Lesion studies 
have demonstrated brain lateralization in immunomodulation (249). This asymmetry may in 
part explain laterality in the histological changes caused by Ap, because the deposits may 
act as antigens to activate the immune system. It is possible that the histological effects of 
AP may not be as reversible in old animals that have compromised metabolic functions. 
However, these transient effects do not exclude the use of young animals injected with AP 
as a model for the initial pathological changes that occur in AD. Based on observations in 
Down's syndrome patients, the histopathology in AD is likely to begin at an early age and it 
is important to slow its progression in its infancy. An animal model using young rats in 
which the pathological changes peak within 2 months following injection may, therefore, 
serve as a relatively inexpensive and efficient tool to screen drugs that may interfere with 
the fibrillogenesis of AP, enhance its degradation, and/or attenuate its toxicity. 
Electrolytic lesions of the amygdaloid complex (51,73, 163,305), lesions of the 
central nucleus (118, 160,350), or of the lateral and basal nuclei of the amygdala (159) 
enhance exploratory behavior of rats in the open field test. No significant difference was 
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observed between the treatment groups in any of the parameters examined in the open field, 
except that the AP treated rats emitted significantly more rears than their respective VEH 
group (Figure 278; p<0.016). Lesions of the amygdala have been shown to be associated 
with behavioral impairments in active avoidance learning (30,286), but do not appear to 
impair spatial learning in the Morris water maze (58,330). Lesions of the hippocampus 
severely disrupt spatial learning (257,278) and this impairment has been shown to be 
potentiated by amygdaloid lesions (1,267). Therefore, because intra-amygdaloid injections 
of AP induce histopathological changes not only within the amygdala but also at distal sites 
including the hippocampus, it was considered appropriate to use the water maze test. No 
behavioral differences were observed between the treatment groups in the one-way CAR 
(Table 1) or in the water maze (Figure 28 A,B). Overall, the lack of severe behavioral 
impairments in this study may be explained by the lack of extensive neuronal loss and/or by 
the laterality in the histopathological effects of Ap. The left hemisphere may compensate 
for the impairments within the right hemisphere. 
The amygdala receives a prominent cholinergic input from the nucleus basalis 
(35,363), and ChAT activity has been reported to be severely reduced within the amygdala 
in AD patients (258,287,288). Measurements of amygdaloid ChAT activity were performed 
to investigate if the cytoskeletal changes and neuronal shrinkage within the amygdala were 
associated with a reduction in ChA T activity. No differences were observed in amygdaloid 
ChAT activity between the treatment groups (Table 2). These data suggest that AP induced 
histopathological changes within the amygdala are not associated with a loss of cholinergic 
terminals projecting from the nucleus basalis. Alternatively, AP induced damage of 
cholinergic terminals within the amygdala may lead to compensatory increase in ChA T 
production within the cell bodies in the nucleus basalis. To investigate these possibilities, it 
would be necessary to analyze ChAT activity within the nucleus basalis and/or to stain for 
ChAT on brain sections. 
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Overall, we have demonstrated reproducible histopathological effects of intra-
amygdaloid injections of A~, that may simulate the initial histopathological changes that 
occur in AD. Alternatively, this approach models the in vivo histopathological effects of 
deposition of A~ fibrils containing the same ~-sheet structure that is observed in senile 
plaques in AD. Furthermore, in young inbred male Fischer-344 rats these changes are in 
part transient, and are predominantly observed within the right amygdala and hippocampus. 
Identification of the cause for the lateralized effect of A~ 25-35 may prove valuable by 
giving insight into possible therapeutic strategies to slow the progression of AD. These 
findings support the use of this rat model as a reliable tool to screen drugs that may alter 
the initial pathological events associated with AD, that occur before the manifestations of 
extensive behavioral impairments. 
CHAPTER VI 
GENERAL DISCUSSION 
We have demonstrated that unilateral intra-amygdaloid injections of amyloid-P (AP) 
25-35 in Fischer-344 rat induce the appearance of abnormal tau proteins both within the 
ipsilateral amygdala, as well as at distant sites as recognized by the tau-2 and Alz-50 
antibodies (317). These cytoskeletal changes were progressive (8 vs. 32 days) and 
associated with reactive astrocytosis. Studies have reported local effects of AP injections 
immediately surrounding the injection site in rat cerebral cortex and hippocampus 
(91, 178, 180), but this is the first report on AP injections into the rat amygdala and their 
distal effects. 
We also examined the time course of the histopathological effects of bilateral 
injections of AP 25-35 and sought to determine if these effects were associated with a 
reduction in choline acetyltransferase (ChAT) activity and behavioral impairments (31 5,316). 
AP 25-35 induced abnormal neuronal tau-2 and interleukin-1 p staining, and reactive 
astrocytosis within the amygdala, as well as at distal sites such as the hippocampus. These 
histological changes were associated with neuronal shrinkage within the amygdala. 
Surprisingly, these changes were predominantly observed within the right hemisphere with 
the left hemisphere significantly less affected. The effects of AP 25-35 peaked at 32 days 
postoperatively. These histopathological effects were not associated with a reduction in 
amygdaloid ChAT activity at 32 days postinjection. This is the first report that 
demonstrates a laterality in the histopathological effects of AP, and it also shows that the 
effects of single intra-amygdaloid injections are in part transient. 
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In a separate experiment, behavioral effects of bilateral intra-amygdaloid injections of 
AP 25-35 were analyzed 34-52 days postoperatively. In the open field test, the treatment 
groups differed only in the numbers of rears emitted (p =0.016). There was no treatment 
effect in the Morris water maze or in the acquisition and retention of a one-way conditioned 
avoidance response. Thus, in young rats, AP induced histopathological changes are not 
accompanied by major behavioral deficits, perhaps because the pathology is restricted to the 
right hemisphere. The lack of extensive neuronal loss may also explain the lack of 
behavioral deficits. 
Together, these findings suggest a direct association between plaque and tangle 
formation in Alzheimer's disease (AD), and support the use of this rat model to screen drugs 
that may alter the initial pathological events associated with AD, that occur before the 
manifestations of extensive behavioral impairments. 
In an attempt to evaluate this model of the initial histopathological effects in AD, it is 
necessary to compare it to reports of other animal models of this disease. It is clear that the 
early animal models of AD (84, 134, 195), that attempted to mimic the loss of cholinergic 
neurons in the basal forebrain in AD (12,57,351 ), are of limited use as a model of AD, 
because they lacked the broad spectrum of pathological features of the disease. Neurons 
producing norepinephrine, serotonin, dopamine, glutamate, y-aminobutyric acid, 
somatostatin, neuropeptide Y, corticotrophin releasing factor, substance P, and other 
neuromodulators are also affected in AD (54,56, 157, 177,288,327). Because of these 
broad deficits in neurotransmitter systems, it is unlikely that AD can be treated by 
transmitter replacement therapy alone. A more feasible approach is to develop compounds 
that interfere with neuritic plaque and tangle formation, the major histopathological 
hallmarks of the disease. 
The discovery of AP as a major component of senile plaques and subsequent 
findings of its in vitro neurotoxicity led to reports examining the in vivo effects of AP by 
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microinjections of Aj3 into the brains of rats and monkeys. The toxic effects of Aj3 in vivo 
have been inconsistent (42,91,99, 101, 102, 178, 180, 191,274,314-317,320,354). This 
may be due to variations in: 1) conformational state (25,269,273), dose, and sequence of 
Aj3; 2) method of administration; 3) pathological endpoints measured; 4) what brain region 
and/or hemisphere is injected; 5) postoperative interval; and, 6) species and/or strain used. 
It can be argued that because Aj3 1-42 is the most prevalent form of Aj3 in senile plaques, it 
is appropriate to use that peptide for injections into brain instead of Aj3 25-35. However, 
the main problem with using Aj3 1-42 is its insolubility in physiological solvents. Therefore, 
there is a risk of potentially toxic solvents interfering with the properties and effects of Aj3 
1-42. On the other hand, Aj3 25-35 is readily soluble in H20 and acquires the same 13-
pleated sheet conformation as Aj3 1-42, which is the toxic conformation of Aj3. In addition 
to injections of Aj3 alone, coadministration of heparan sulfate proteoglycans has been shown 
to be important for consistent in vivo deposition and persistence of fibrillar Aj3 in the rat 
hippocampus (321 ). Our studies represent the only comprehensive time course study that 
has been reported on the histopathological effects of Aj3, and shows in contrast to other 
studies ( 102,321) that Aj3 deposits can be observed consistently without coadministration 
of other compounds and that these deposits are not degraded following intracerebral 
administration in the rat. The reason for these discrepancies may be due to variations in 
some of the experimental procedures mentioned above. For example, acetylcholinesterase 
(AChE) has been shown to promote the formation of and/or stabilization of Aj3 fibrils (150), 
and the basolateral amygdala, that is adjacent to the injection site in our studies, has one of 
the highest levels of AChE of any brain structure (261 ). 
Before our reports, a few in vivo studies had investigated the potential association 
between plaque and tangle formation in AD by examining the effects of Aj3 injected into the 
brain on tau IR (42,91,99, 178, 180,274). Some of these studies indicated that Aj3 can 
induce the appearance of abnormal tau proteins in the vicinity of the injection site (rat 
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cerebral cortex and hippocampus) (91, 178, 180). Other studies failed to show any effect 
(42,99,274). For the most part, these in vivo studies were only qualitative or descriptive in 
nature. Our reports are the first to attempt to quantify Af3 induced effects by counting 
neuronal tau IR cells, to demonstrate distal cytoskeletal and astrogliotic changes, and to 
investigate the time course of these histopathological effects of Af3. Overall, these findings 
suggest an association between plaque and tangle formation in AD. It should be noted that 
the rodent brain does not spontaneously form senile plaques or neurofibrillary tangles (50), 
the main histopathological hallmarks of AD. Human and rodent Af3 differ in three amino 
acids. As a consequence, the rat Af3 is much less fibrillogenic than the human Af3 (72) and 
that may explain the lack of senile plaques in rodents. Rodent tau differs also from human 
tau (3) and that may explain the lack of tangles in rodents. Tangles are formed in several 
human neurodegenerative diseases besides AD (357) and may be a marker of specific form 
of cell injury, such as slow neurodegeneration, in some but not all mammals. 
The effects of Af3 on tau IR may be mediated through an increase in intracellular 
calcium. Af3 has been shown to increase intracellular calcium (7,218), and calcium influx in 
cultured rat hippocampal neurons caused by glutamate induces tau IR as recognized by the 
antibodies Alz-50 and 5E2 (216). Protein kinases are generally activated by increases in 
intracellular calcium and several of those have been shown to phosphorylate different sites 
on tau proteins (238). Therefore, Af3 may increase the phosphorylation of tau proteins 
through an activation of kinases mediated by an increase in intracellular calcium. The 
activities of some phosphatases that may dephosphorylate tau proteins have been shown to 
be decreased in AD (111,311 ). Therefore, Af3 25-35 may also be decreasing the 
dephosphorylation of tau proteins through an inhibition of phosphatases. 
There have been reports on the effects of intracranial Af3 injections on behavior. 
These behavioral studies are difficult to compare because the experimental procedures 
varied substantially. Because of the nature of behavioral experiments it is necessary to 
support alterations in behavior with neurochemical and/or histological findings. It is 
interesting to note that although several of these studies demonstrate behavioral 
impairments following A~ injections, few of these reports investigated the time course of 
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the histopathological and/or neurochemical changes caused by A~, to determine the most 
appropriate postoperative interval to perform behavioral testing. It is possible that the 
behavioral effects observed in some of these studies may be due to physical displacement of 
brain tissue by high doses of A~ rather than actual histopathological effects. The behavioral 
effects obtained in our model were modest. In the three tests performed, there was a 
significant difference between the treatment groups only in the number of rears in the open 
field. These results were not surprising mostly because of the lateralized effects of A~. 
There is a consensus in the field of behavioral neuroscience that bilateral lesions are often 
necessary to obtain behavioral deficits, because of compensation by the unlesioned side. 
Although there have been several reports on transgenic approaches to model AD 
(53,98, 137-139, 143, 145, 146, 186, 188,206,236,263,277,364) only two of these reports 
appear to be promising (98, 145). These two mouse models contain age dependent compact 
congophilic A~ plaques similar to those observed in AD, and in one of these models these 
changes are associated with behavioral impairments (145). The first of these models to be 
described overexpresses amyloid-~ precursor protein (APP) containing the APP71 7 mutation 
that is associated with familial AD (98). These mice express 8-10 fold the normal level of 
APP and have large numbers of amyloid plaques in the hippocampus, corpus callosum, and 
cerebral cortex that first appear at 6-9 months of age. The majority of the plaques are 
associated with reactive astrocytes and dystrophic neurites. The neocortices of these mice 
exhibit diffuse synaptic and dendritic loss, and contain diffusely activated microglia. This 
histopathology is region specific and age dependent as in AD, despite expression of the APP 
transgene throughout the brain. These results suggest that region and/or cell type specific 
vulnerability of the aging brain may dictate the pattern of plaque formation. A significant 
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limitation of this model is the lack of neurofibrillary tangles, and their absence may reflect 
species variations in neuronal response to injury. Also, in this model there have been no 
reports of behavioral impairments associated with the histopathological changes. 
The other promising transgenic mouse model (145) overexpresses a mutated form of 
APP695 that has been found in a Swedish family with early-onset AD (242). These mice 
express this human form at 5-6 fold the levels of endogenous mouse APP, that remains 
unchanged between 2 and 14 months of age. These mice demonstrate normal learning and 
memory in the Morris water maze and the Y maze at 3 months of age but are impaired by 9 
to 10 months of age. A 5 fold increase in AP 1-40 and a 14 fold increase in AP 1-42 is 
associated with these behavioral deficits. Numerous Congo red positive AP plaques are 
present in mice with elevated AP levels. The distribution of the histopathological changes is 
reportedly similar to that observed by Games et al. (98). The authors indirectly control for 
impairments in motor performance but it is possible that the behavioral deficits may be 
caused by visual impairments. This possibility, overlooked by the investigators, is based on 
the impairment of the transgenic mice in swimming to a visible platform. Interestingly, other 
transgenic approaches that are not associated with AD-like histopathology (146,364), or 
that have only diffuse AP deposits that are not congophilic and lack neuritic involvement 
(139), have been reported to lead to deficits in spatial memory in the Morris water maze 
(236,364) and in the Y maze (146,236). As in the model by Hsiao et al. (145), both of the 
models tested in the water maze showed significant impairments in initial learning 
(236,364), suggesting that gene dosage effect or position effect of transgene integration 
but not the AP deposition per se may lead to behavioral deficits. Furthermore, as in the 
Hsiao model, the mice with the diffuse AP deposits ( 139) exhibited greater latency in 
locating a visible platform in the water maze (236). This observation further suggests that 
visual impairments may account for differences in performance. Interestingly, APP and AP 
are present at low levels in normal lenses and AP has toxic effects on lens epithelial cells 
139 
(94). APP is synthesized in retinal ganglion cells and transported into the optic nerve, in 
which C-terminal amyloidogenic fragments accumulate (237), and there is an increased APP 
IR in retinal ganglion cells of the elderly (198). Together, these findings emphasize the 
importance of investigating possible vision impairments in APP transgenic animals. 
In contrast to other APP transgenic models, the expression of the APP variant in 
these two promising models (98, 145) substantially exceeds those of the endogenous mouse 
APP gene. Because of the various proposed roles for APP, it is likely that a 5-1 O fold 
increase in APP has several biological effects beside an increase in AP production and 
subsequent plaque formation. There is no compelling evidence that sporadic AD is 
associated with a global increase in APP expression (115). It is also possible that insertion 
of multiple copies of any gene construct may impair cognitive function, because inheritance 
of relatively small amounts of extra genomic DNA in human imbalanced translocation 
karotypes results in mental retardation (364). The behavioral effects may also be due to 
position effect of transgene integration that may interfere with the expression of other 
genes. 
Even though several in vitro studies have tested various hypotheses for the 
mechanism by which AP exerts its toxic effect, these hypotheses have not been adequately 
tested in in vivo situations. It is important to continue to explore the in vivo effects of AP 
by direct injections into brain. Findings from these studies may help elucidate the sequence 
of pathogenic events that ultimately lead to AD. In conjunction with transgenic models they 
may also distinguish between the biological effects of AP and elevated levels of APP, 
respectively. 
Animal models can be evaluated in terms of construct validity, face validity and 
predictive validity. We believe that our model has construct validity because we are 
injecting a fragment of a peptide, that may play a prominent role in the etiology of AD, into 
a brain region that is affected early in the disease. The most appropriate face validity of an 
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animal model of AD would be the demonstration of senile plaques associated with reactive 
astrocytes, neurofibrillary tangles, and neuronal shrinkage and cell loss in the same brain 
regions as observed in AD. It is unlikely, however, that this effect can be obtained using a 
single injection of A~ into rat brain, but this approach may demonstrate the early 
histopathological changes in AD. In my opinion, the present rat model has a relatively high 
face validity because of the neuronal shrinkage and the induction of abnormal tau proteins 
and reactive astrocytes in brain regions where the primary and early histopathological 
changes in AD are observed. Currently, no definitive transgenic animal models are available 
that resemble all aspects of AD, although plaque-like A~ deposits have been observed 
(98, 145), that in one model are associated with behavioral impairments (145). The 
predictive validity of the present rat model, as well as current transgenic models, will 
ultimately determine their usefulness in screening potential drugs for therapy. 
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Af3 deposits (senile plaques) 
JI' ' ~ * Neuronal shrinkage * Reactive astrocytes 
and microglia 
* Abnormal tau proteins 
(Neurofibrillary tangles) 
Neuronal death 
' 
* Neurochemical deficits 
' 
* Behavioral impairments 
' Clinical Alzheimer's disease 
Figure 29. Pathological effects of Af3. A flow diagram showing a proposed scenario for the 
pathological effects of Af3. The star symbol (*) represents phenomena analyzed in rats in 
the present study. This figure represents an extremely simplified version of some of the 
pathological processes that may be involved in the progression of AD. 
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Future Directions 
Because AD is an age related disorder it is necessary to investigate the effects of 
intracerebral injections of A~ in old animals. A detailed histological analysis of the whole rat 
brain following intra-amygdaloid injections of A~ will certainly be valuable. A comparison of 
the regional pattern of histopathology with efferent and afferent projections of the amygdala 
may provide insight into the mechanism of A~ effects. However, a lack of pathology in a 
brain region that has prominent projections to the amygdala will not necessarily disprove the 
hypothesis that A~ may be affecting nerve terminals. In AD there is a selective vulnerability 
of brain regions and the pathological process occurs over decades. It is possible that 
different regions and/or cell types of the brain have different kinetics and/or vulnerability for 
A~ induced pathology. It would also be interesting to determine if multiple A~ injections 
administered through implanted cannula could lead to more severe behavioral impairments 
than we observed following single injections. Behavioral testing using different behavioral 
paradigms and/or postoperative interval may also be useful. The laterality observed 
following bilateral intra-amygdaloid injections is a very surprising phenomenon. It is 
important to determine if the laterality in the effects of A~ is specific for the amygdala, or if 
it can be observed following injections into other brain structures or following ventricular 
infusions. Injections of A~ into other strains and species are necessary to determine if the 
histopathological effects and/or laterality are strain and/or species specific. Further 
investigations into the cause for the lateralized effects of A~ are also warranted. In 
addition, injections of A~ 1-40, A~ 1-42, and other amyloidogenic peptides, co-injections of 
other plaque components, and even injections of senile plaque cores may provide clues on 
how prominent role the ~-sheet structure of A~ has in the process of AD histopathology. 
Finally, it would be interesting to determine if compounds that interfere with A~ fibril 
formation and/or enhance fibril degradation in vitro could affect A~ deposition and/or 
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accelerate the in vivo degradation of the deposits. Anti-inflammatory compounds that easily 
penetrate the blood-brain-barrier are also of potential interest to attenuate the 
histopathological effects of intracerebral injections of A~. 
Conclusion 
In summary, the present model has histopathological features that are likely to occur 
in the initial stages of AD but its predictive validity will ultimately determine its usefulness as 
an animal model for AD. 
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